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SUMMARY 
 
Due to their speed and lack of photonic interferences MALDI MS assays have a great potential 
to support drug discovery. Previous work demonstrated the feasibility of whole cell-based 
MALDI MS assays for abundant pharmacodynamics protein markers. Analogous assays for 
metabolites, which are of interest for phenotypic and mechanistic drug profiling studies due to 
their potentially high dynamic range, have been missing. In this thesis a score-based method 
development approach was implemented to develop a metabolite-based whole cell MALDI MS 
fingerprinting workflow. The final workflow enabled optimized discrimination of three cancer 
cell lines by principal component analysis. This MS fingerprinting workflow was used for 
development of the first metabolite-based phenotypic MALDI MS assay, in this case to monitor 
BCR-Abl tyrosine kinase inhibition in K562 leukemia cells. To add to the strength of this 
workflow, a data processing pipeline was developed in R programming language for the 
automated extraction of drug-sensitive m/z features. This data processing pipeline enabled the 
extraction of metabolite concentration-response markers that were structurally characterized 
by ultra-high resolution MALDI-FTICR MS/MS. To this end, heme B, a known marker for 
erythropoiesis in K562 cells, was identified as a suitable phenotypic marker of redifferentiation 
of these leukemia cells. The potassium adduct of the membrane lipid phosphatidylcholine 
(36:1) enabled to compare potencies of different tyrosine kinase inhibitors. In the second part 
of this thesis, the first MALDI MS-based mechanistic cell assay was developed, using inhibitors 
of the fatty acid synthase (FASN) as an example. Here, the employment of a 13C-labelled 
internal isotope standard enabled standardized monitoring of cellular malonyl-CoA 
accumulation upon FASN inhibition. Automation enabled assays in 96-well format. The 
dynamic range of the signal readout and Z-factors suggested excellent assay performance. 
Exploratory, unbiased data analysis followed by MS/MS structural characterization revealed 
CDP-choline as a generalized marker for lipid pathway inhibition, which not only responds to 
confirmed FASN inhibitors but also to the acetyl-CoA carboxylase inhibitor TOFA. The assay 
confirmed publications highlighting BI 99179 and GSK2194069 as potent FASN inhibitors but 
also gave evidence that a third inhibitor, triclosan, which also was published as a FASN 
inhibitor, indeed affects the lipid synthesis pathway at one synthetic step, but most likely not 
FASN activity. In conclusion, this thesis demonstrated that metabolite-based MALDI MS cell 
assays – both phenotypic and mechanistic - are feasible, standardizable, and automatable, 
and that they generate robust data useful for chemical biology work or compound profiling in 
drug discovery. Future work is likely going to focus on scaling up the throughput of MALDI MS 
cell assays by miniaturization and automation as well as expanding the repertoire of metabolic 
enzymes targetable by MALDI MS cell assays. 
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ZUSAMMENFASSUNG 
 
Aufgrund ihrer Schnelligkeit und des Fehlens photonischer Interferenzen haben Matrix-unter-
stützte Laser-Desorptions-/Ionisations (MALDI) Massenspektrometrie (MS) -Assays ein 
großes Potenzial, die Entdeckung neuer Wirkstoffe zu unterstützen. In früheren Arbeiten 
wurde die Durchführbarkeit von MALDI MS-Zellassays für abundante pharmakodynamische 
Proteinmarker gezeigt. Bislang gab es jedoch keine analogen Assays für Metabolite, die 
aufgrund ihres potentiell hohen dynamischen Bereichs für phänotypisches und 
mechanistisches Wirkstoff-Profiling von Interesse sind. In dieser Dissertation wurde ein 
kennzahlenbasierter Ansatz zur Methodenentwicklung implementiert, um einen 
metabolitbasierten MALDI MS-Fingerprinting-Workflow für ganze Zellen zu entwickeln. Der 
finale Workflow ermöglichte die optimierte Unterscheidung von drei Krebszelllinien mittels 
Hauptkomponentenanalyse (PCA). Der MS-Fingerprinting-Workflow wurde für die Entwicklung 
des ersten metabolitenbasierten, phänotypischen MALDI MS-Assays verwendet, in diesem 
Fall, um die Inhibition der BCR-Abl-Tyrosinkinase in K562-Leukämiezellen zu messen. Um die 
Leistungsfähigkeit des Workflows zu erhöhen, wurde mit Hilfe der Programmierumgebung R 
eine Datenverarbeitungspipeline zur automatisierten Extraktion von wirkstoffsensitiven m/z-
Werten entwickelt. Diese Datenverarbeitungspipeline ermöglichte die Extraktion von 
Metabolit-Konzentrations-Wirkungs-Markern, die mittels ultrahochauflösender MALDI-FTICR 
MS/MS strukturell charakterisiert wurden. Häm B, ein bekannter Marker für Erythropoese in 
K562-Zellen, wurde als geeigneter phänotypischer Marker für die Redifferenzierung dieser 
Leukämiezellen identifiziert. Das Kaliumaddukt des Membranlipids, Phosphatidylcholin (36:1), 
ermöglichte den Vergleich der Potenzen verschiedener Tyrosinkinase-Inhibitoren. Im zweiten 
Teil dieser Arbeit wurde am Beispiel der Inhibition der Fettsäuresynthase (FASN) der erste auf 
MALDI MS basierende mechanistische Zellassay entwickelt. Die Verwendung eines 13C-
markierten Standards ermöglichte eine standardisierte Überwachung der zellulären Malonyl-
CoA-Akkumulation nach FASN-Inhibition. Automatisierung ermöglichte die Durchführung des 
Assays im 96-Well-Format. Der dynamische Bereich des Signals sowie der Z-Faktor deuteten 
auf einen hervorragenden Assay hin. Explorative Datenanalyse gefolgt von MS/MS-
Strukturcharakterisierung ergab, dass CDP-Cholin als genereller Marker für die Inhibition der 
Phospholipid-Biosynthese fungiert, der nicht nur auf bestätigte FASN-Inhibitoren, sondern 
auch auf den Acetyl-CoA-Carboxylase-Inhibitor TOFA anspricht. Der Assay bestätigte 
Publikationen, in denen BI 99179 und GSK2194069 als potente FASN-Inhibitoren 
hervorgehoben wurden, wies jedoch auch darauf hin, dass ein weiterer Inhibitor, Triclosan, der 
ebenfalls als FASN-Inhibitor veröffentlicht wurde, tatsächlich die Lipidsynthese an einem 
Syntheseschritt beeinflusst, jedoch nicht die FASN-Aktivität. Zusammenfassend konnte in 
dieser Arbeit gezeigt werden, dass - sowohl phänotypische als auch mechanistische - 
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metabolitbasierte MALDI-MS-Zellassays durchführbar, standardisierbar und automatisierbar 
sind und robuste Daten liefern, die für die chemische Biologie oder das Wirkstoffprofiling 
nützlich sind. Zukünftige Arbeiten werden sich voraussichtlich auf die Erhöhung des 
Durchsatzes von MALDI MS-Zellassays durch Miniaturisierung und Automatisierung sowie die 
Erweiterung des Repertoires an Enzymreaktion, die durch MALDI-MS-Zellassays nachverfolgt 
werden können, fokussieren. 
 
1 INTRODUCTION 
 
1.1 MASS SPECTROMETRY 
 
Mass spectrometry (MS) is an analytical technique used to ionize chemical species and sort 
them based on their mass-to-charge ratio (m/z). Mass spectra are typically plots of m/z values 
against their ion intensities and can be used to determine the isotopic distribution of an atom 
or molecule [1], the chemical structure of a molecule [2], or a species or molecule specific 
pattern also called fingerprint [3]. 
A mass spectrometer typically consists of an ion source to ionize gaseous, liquid or solid 
samples, a mass-analyzer to separate the ions by m/z in an electric or magnetic field, and a 
detector to detect charged molecules [4]. If the formation of gas phase ions involves extensive 
fragmentation of the analyte, the ionization technique is referred to as ‘hard’, whereas 
ionization techniques without extensive fragmentation are referred to as ‘soft’ [5]. 
Accurate mass measurements require a high mass resolution to rule out the interference with 
signals corresponding to ions of different elemental compositions. Mass resolution is defined 
as the closest distance between two distinguishable peaks of equal width and height [6]. The 
term resolving power is defined as the quotient of the mass resolution and the measured m/z. 
Mass accuracy, is defined as the quotient of the m/z measurement error (Δm) and the true 
m/z. Mass accuracy is typically measured in parts per million (ppm). 
To date, a wide variety of methods to transfer charged ions into the gas phase have been 
described. Among these methods matrix-assisted laser desorption / ionization (MALDI) has 
become an irreplaceable part in biological science [7]. 
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1.1.1 BASICS OF MALDI MS 
 
MALDI is a relatively impurity tolerant and sensitive ionization method that is characterized by 
relatively little fragmentation of the analyte [8]. Prerequisite for MALDI is the incorporation of 
the analyte molecules into a crystalline matrix. The analyte is desorbed from the target plate 
by irradiating matrix:analyte co-crystals with a pulsed laser beam. After the desorption and 
ionization, the analyte molecules are separated according to their respective m/z values in the 
mass analyzer [9]. Although the MALDI ionization process is not fully understood, two 
descriptive models have found scientific acceptance: 
The Gas Phase Protonation model proposes two steps that lead to the formation of analyte 
ions. In the first step, laser irradiation produces matrix ions through photoionization. In the 
second step, the charge is transferred to the neutral analyte molecules [9, 10]. 
The Lucky Survivor model proposes that the extent of ionization depends on the solvent and 
matrix used during sample preparation. According to the model, the solvent and matrix transfer 
charges to the analyte. Subsequently, the charged analyte is incorporated into the matrix 
crystal. Laser induced desorption releases charged clusters of analyte and matrix into the gas 
phase. Charge transfer among analyte and counterions might either result in quantitatively 
neutralized clusters that are not detectable. In cases of charge excess due to charge 
separation during the disruption of the matrix crystal, the lack of counterions favors the 
formation of charged analytes – the lucky survivors [9, 11]. It might well be possible that both 
models are involved in the formation of analyte ions (Fig. 1.1.1) [10]. 
Time of flight (TOF) analysis is well suited for the pulsed ion generation by MALDI. The 
generated ions are accelerated in an electric field (Fig. 1.1.2 A). The time required to pass a 
flight tube (tof) is dependent on the mass (m) and the charge of the particle (q): 
𝑡𝑜𝑓 = 𝑘 √
𝑚
𝑞
 
where k is a proportionality factor, that includes among other the length of ion source and flight 
tube as well as the extraction potential. TOF measurements can be applied over a broad mass 
range since the analyzer can be operated in both linear (2 - >100 kDa) and reflector mode (0 
– 2000 Da) [12]. In linear mode the ions are directly accelerated towards the detector. In 
reflector mode the accelerated ions are redirected in an ion mirror (reflector) at the end of the 
flight tube to compensate slight differences in kinetic energy. Thereby mass resolution and 
accuracy are increased.  
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Figure 1.1.1: The MALDI process. The analyte is embedded into a MALDI matrix on a sample 
carrier. A pulsed laser beam irradiates the sample. Two complementary models are used to 
describe the subsequent desorption and ionization: I) According to the Gas Phase Protonation 
model, neutral analyte molecules are charged by gas phase collisions with charged matrix-
molecules. II) The lucky survivor model proposes that the charged analyte breaks out of a 
cluster of ions that predominantly neutralize each other. The charged analytes enter the mass 
analyzer. Note that the model is not only valid for the generation of positively charged ions (as 
illustrated) but also for negatively charged ions. 
 
MALDI-TOF MS has been applied to a broad range of biological analytes like proteins in linear 
mode as well as peptides, glycans, lipids and metabolites in reflector mode. Typical mass 
resolutions in linear and reflector mode are 5,000 and 20,000, respectively. For higher mass 
resolutions of 100,000 and above, the MALDI sources are coupled to mass analyzers like the 
Fourier Transform (FT) Ion Cyclotron Resonance (ICR) analyzer [13].  
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Figure 1.1.2: Common mass analyzers combined with MALDI. A) During a MALDI-TOF 
measurement, gas phase ions enter the TOF analyzer upon acceleration in an electric field. 
For linear ion mode measurements, ions directly pass the flight tube towards the linear 
detector. For measurements in reflector ion mode, an ion mirror, i. e. reflector, is interposed 
prior to the linear detector. Low molecular mass molecules are redirected and describe an 
inverted U-shaped flight pass towards the reflector detector. B) During a MALDI-FTICR 
measurement ions enter a strong magnetic field, in which they are kept on circular trajectories 
through excitation to their cyclotron resonance frequency. The movement of charged 
molecules in a magnetic field induces a voltage at the detection plates. The obtained frequency 
spectrum can be converted into a mass spectrum through Fourier transformation. 
 
In FTICR MS charged particles, e.g. ions, are trapped in an orthogonal magnetic field between 
two electric plates (Penning Trap) by a force called “Lorentz Force“ (Fig. 1.1.2 B). An 
instrument that excites these circulating ions to larger trajectories by an oscillating electric field 
is called ICR mass spectrometer. The frequency at which an ion moves in a magnetic field is 
characteristic for its mass and can be measured by electrodes. The measured signal is a 
superposition of sine waves, called free induction decay (FID). Fourier transformation of the 
FID results in a mass spectrum [14].  
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1.1.2 HISTORICAL VIEW ON THE DEVELOPMENT OF MALDI MS 
 
In the early 1910s, Joseph John Thomson invented an instrument that was able to measure 
the electron to mass ratio (e/m) and thereby indirectly enabled to determine the mass of e. 
Thomson was awarded the Nobel Prize in Physics in 1906 for investigating the electron1. 
Together with Francis Aston, who was awarded the Nobel Prize in Chemistry in 1922, 
Thomson built the first mass spectrometer that was able to measure the mass of charged 
atoms [15]. In the beginning of the 20th century mass spectrometry was mainly used to 
separate elemental isotopes which was of particular importance for the separation of 235U, the 
isotope suitable for nuclear fission from 238U in the nuclear weapons program during World 
War II [16]. 
In 1985, Karas, Bachmann and Hillenkamp demonstrated that the addition of small UV-
absorbent molecules as a matrix facilitates the detection of non-absorbing molecules [17]. The 
great advantage of this method is an almost fragmentation free, soft ionization. The 
development of MALDI for nonvolatile molecules advanced the use of TOF mass analyzers, 
which until then were only of interest for the rather exotic studies on charged atoms [18]. 
In 2002, the Nobel Prize in Chemistry was awarded one fourth to Koichi Tanaka for the 
“development of soft desorption ionization methods for mass spectrometric analyses of 
biological macromolecules"2. Tanaka had developed a method where the sample is deposited 
on the surface of a liquid matrix containing glycerol and cobalt powder [19]. The method has a 
poor sensitivity compared to MALDI where the analyte is mixed with a crystalline matrix. For 
this reason MALDI was embraced by the scientific community [15]. 
MALDI-TOF mass spectrometers were commercially available since the early 1990s. The first 
integrated MALDI-TOF instrument and software solution for routine clinical use was the MALDI 
Biotyper. In 2012, the MALDI Bioytyper got FDA approval for diagnostics of cultured bacteria 
from human specimens [20]. 
Novel applications like MALDI MS imaging and high throughput MALDI MS assays were 
facilitated by novel mass spectrometers with much increased speed of data acquisition 
provided, for example, by new lasers such as a Smartbeam 3D 10 kHz frequency-tripled 
Nd:YAG laser. Early MALDI-TOF instruments required 1-2 minutes / data point, however 
                                               
1 Nobelprize.org (1906) The Nobel Prize in Physics 1906. 
https://www.nobelprize.org/nobel_prizes/physics/laureates/1906/. 
2 Nobelprize.org (2002) The Nobel Prize in Chemistry 2002. 
https://www.nobelprize.org/nobel_prizes/chemistry/laureates/2002/index.html. 
- 8 - 
advances in laser technology and data acquisition methodology enable the latest mass 
spectrometers to have a sampling rate of 50 data points / s [21]. 
 
1.1.3 MALDI MS WHOLE CELL ASSAYS 
 
The terms whole cell (WC) or intact cell (IC) measurements refer to methods in which cells are 
directly subjected to MS analysis without prior fractionation or extraction. Despite the fact that 
omitting pre-purification steps reduces sensitivity, IC-MALDI MS has been appreciated for its 
speed, robustness, low cost, and ease of automation early on [3]. The development of whole 
cell-based MALDI MS assays went hand in hand with advances of the MALDI MS technology 
(Fig. 1.1.3). 
The first whole cell measurements were described by Anhalt et al. in 1975 [22]. The study team 
had directly inserted lyophilized bacteria into the heated ion source of a plasma ionization mass 
spectrometer and observed species-specific pyrolysis products of ubiquinones and 
phospholipids. The publication had opened the field of species-specific pattern recognition, 
also referred to as fingerprinting or biotyping, using mass spectrometry.  
In 1996 Holland et al. were the first to implement MALDI-TOF MS for bacterial biotyping. Since 
that time MALDI MS biotyping has been established as an important tool in both environmental 
microbiology and clinical diagnostics of pathogenic bacteria [23]. 
In more recent years, MALDI biotyping has also been applied to mammalian whole cells. The 
Lam and the Hopf laboratories were among the first to develop MALDI MS-based biotyping 
methods for the, compared to bacteria, more complex mammalian cells. In a seminal study 
Zhang et al. generated protein fingerprints that enabled one to distinguish different cell lines 
[24]. The publication had a strong focus on the identification of the underlying proteins which 
were mainly abundant proteins like ribosomes and histones. In contrast, Munteanu et al. 
centered method development on the generation of a standardized protein fingerprint from 
whole mammalian cells [25]. The method was able to reproducibly distinguish cell lines and 
primary cells in PCA space. Due to its robustness, this method is suited to characterize cells 
during bioprocesses [26, 27]. 
The first pharmacological relevant studies using IC-MALDI MS were also protein-based. Dong 
et al. described an IC-MALDI MS assay to detect apoptosis-based on specific features that 
were reproduced in several different cell lines [28]. The first quantitative drug target 
engagement study using IC-MALDI MS was reported by Munteanu et al. in 2014 [29]. The 
group was able to derive IC50 values of histone deacetylase inhibitors by quantifying histone 
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acetylation specific mass shifts. These mass shifts were directly observed in the IC-MALDI 
fingerprint without any sophisticated enrichment steps. 
 
Figure 1.1.3: Technological milestones in the development of IC-MALDI MS. In 1919, 
Thomson and Aston developed the first mass spectrometer for charged atoms. In 1975, the 
Fenselau group obtained mass spectra of whole bacteria. Karas and Hillenkamp discovered 
the MALDI process in 1985. In 1996, MALDI-TOF MS was first used for bacteria fingerprinting. 
A decade later, the first end-user friendly MALDI biotyper was launched. Around the same time 
fingerprints of intact mammalian cells were reported in a seminal study. In 2014, histone 
deacetylase drug target engagement was monitored by IC-MALDI. Two years later the rapifleX 
MALDI PharmaPulse for ultra-HTS was released. 
 
By now, protein-based IC-MALDI MS assays have been reported for the use of 
pharmacodynamic characterizations repeatedly [30, 31]. In contrast, metabolite-based IC-
MALDI MS assays to determine IC50 values have not been described thus far.  
Still some notable work has been done in the field already. In 2012 the Corcelli study team 
used MALDI MS to measure lipids from intact mitochondria [32]. In follow-up work, they were 
able to generate a cardiolipin fingerprint of whole leukocytes, which worked as a diagnostic 
tool for Barth syndrome [33]. In 2017, Lobasso et al., found alterations of phospholipids and 
glycosphingolipids in whole cell MS profiles of parkin-mutant human skin primary fibroblasts. 
These alterations are hypothesized to be due to mitochondrial turnover and autophagy [34]. 
In a single pharmacology related study, Sakai et al. compared lipid patterns of benign prostate 
hyperplasia to Degarelix treated prostate cancer cells [31]. The authors monitored global 
changes in the lipid pattern upon treatment with a single concentration of Degarelix. A 
quantitative pharmacodynamic characterization of drug action has not yet been performed by 
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metabolite-based IC-MALDI MS and neither automatable phenotypic or mechanistic MALDI 
MS-based cellular assays exist to date. 
 
1.1.4 SAMPLE PREPARATION AND MULTIFACTORIAL METHOD DEVELOPMENT FOR SMALL MOLECULE-
BASED MALDI MS 
 
Co-crystallization of matrix molecules and analyte is a prerequisite for MALDI. Particularly for 
the detection of peptides and metabolites, the incorporation of the analyte into the matrix 
crystals has substantial impact on the limit of detection [35]. The sample preparation protocol 
for MALDI has been subjected to research for decades. Plenty of preparatory methods have 
been described. 
Commonly used MALDI matrices, that have been described for lipid and metabolite detection 
include 1,5-diaminonaphthalene (DAN) [36], 2,5-dihydroxybenzoic acid (DHB) [37], 6-Aza-2-
thiothymine (ATT) [38], 9-aminoacridine (9AA) [33] and α-cyano-4-hydroxy cinnamic acid 
(HCCA) [39]. 
MALDI matrices are required to form crystals, which enable the incorporation of analyte 
molecules. At the same time the blessing of a well crystallizing matrix is also a burden. When 
applying mixtures of analyte and DHB matrix on a target spot, DHB forms large crystals at the 
periphery of the spot. Best signal intensities are obtained when the UV-laser directly hits these 
crystals, the so called “sweet spots”. The existence of these sweet spots is a main reason for 
signal heterogeneity, poor automation and poor reproducibility [40].  
The reason for crystals growing from the periphery of the spot is the coffee stain effect. 
Evaporation of solvent causes a periphery driven flux inside the droplet. The outward driven 
flow compensates for rapidly decreasing droplet-height at its edges. The analyte molecules 
are pinned at the three phase contact line between solvent, air and steel target [41]. 
To this day, plenty of matrix application methods have been described, but still the gold 
standard is missing. In a classic preparation, which is typically referred to as dried droplet, 
the MALDI matrix is directly mixed with the analyte and applied on the MALDI target. A 
sandwich preparation describes the deposition of an analyte and matrix containing droplet on 
top of a predeposited matrix layer [25]. The predeposited matrix molecules function as anchor-
crystals for the applied solution. Ruh et al. described the PrimaDrop method for lipids where 
the analyte is prespotted on the target plate and the matrix, dissolved in a highly volatile 
solvent, is spotted on top [38]. Fast evaporation of the solvent diminishes the formation of 
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larger crystals while the preparation is aggravated by volatile solvents. In the field of mass 
spectrometry imaging a standard operation is to spray the matrix on top of the specimen using 
capillary flows [42]. Small applied volumes result in a layer of equally distributed, small crystals. 
Hankin et al. introduced the use of matrix sublimation to homogenously coat the sample with 
matrix [43]. In this solvent free system, the matrix crystals grow with the amount of sublimated 
matrix. Kudina et al. enhanced drying of analyte and matrix solutions by electrowetting [41]. 
In an electric field the applied sample spot is exposed to flow fields that counteract the 
molecule-flux driven by evaporation. The preparation requires a non-commercially available 
target plate that enables row wise application of an alternating voltage. 
In addition to matrix preparations and deposition methods, several solvent additives have 
been described to increase method performance. Trifluoroacetic acid (TFA), a strong organic 
acid, increases signal intensities of basic analytes in positive ion mode by decreasing the pKa 
of the matrix [44]. Addition of (alkali) salts has been described to facilitate spectra interpretation 
and to improve detectability of certain lipids since analyte signals are shifted from multiple 
adducts to one forced adduct [45]. 
A multitude of small molecules to facilitate the detection of metabolites and lipids are proposed 
in the literature. Also, the number of parameters that require optimization in the course of 
method development exceeds a dimensionality that can be reduced to visualization and 
evaluation in 2- or 3D space. 
AlMasoud et al. performed fractional factorial design (FFD) to optimize the detection of 5 
lipids [46]. The authors considered 8 different matrices, 11 matrix additives, 5 additive 
concentrations, 6 matrix preparation methods and 3 deposition methods as important factors. 
The FFD algorithm selected the lowest number of experiments to sufficiently describe the 
underlying problem and reduced the possible 8064 experiments to 720 key experiments. This 
approach is especially helpful if a method is developed from scratch. Despite a reduction of 
experimental effort by more than 90 %, the 720 remaining experiments are still considerably 
cost and time consuming. 
Erich et al. developed an on-tissue digest method for MSI by score-based comparison of four 
state of the art on tissue digestion protocols and combining parts of the methods to a new 
method. They also introduced a method scoring system, which reflects data scattering in 
PCA space. The interclass overlap score Joverlap is the quotient of data scattering within a 
coherent group (WS) divided by data scattering between non-coherent groups (BS). 
𝐽𝑜𝑣𝑒𝑟𝑙𝑎𝑝 =  
|𝑊𝑆|
|𝐵𝑆|
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Even though the score was intended as a tool to measure reproducibility in multivariate space 
[47], Joverlap enables parallel optimization of reproducibility and information content. 
Another valuable score is the matrix suppression effect (MSE) [48]. The MSE occurs when 
sufficient analyte molecules are present in the sample. Ideally all matrix ions are suppressed 
and the spectrum contains only analyte signals. Fülöp et al. published the MSE by lipids score 
(MSElip) as the ratio of the amount of lipid signals (∑ lipids) compared to all signals (∑lipids + 
∑ matrix) for a given mass range [49]: 
𝑀𝑆𝐸𝑙𝑖𝑝  =  
∑ 𝑙𝑖𝑝𝑖𝑑𝑠
∑ 𝑙𝑖𝑝𝑖𝑑𝑠 +  ∑ 𝑚𝑎𝑡𝑟𝑖𝑥
 
 
1.1.5 INTRODUCTION TO PRINCIPAL COMPONENT ANALYSIS 
 
Principal component analysis (PCA) is a widespread tool for dimensionality reduction while 
maintaining the majority of information of the dataset [50]. The use of PCA for dimensionality 
reduction of mass spectra has previously been implemented for the analysis of both MALDI 
MS imaging [51, 52] and fingerprinting [25, 53, 54] data. 
The means by which PCA reduces data complexity while maintaining the majority of the data 
sets’ information, i.e. the variance in the data, is briefly described for a simplified set of 20 
mass spectra consisting of 3 peaks each (Fig. 1.1.4 A)3. The mass spectrum is vectorized and 
projected into a multidimensional space (Fig. 1.1.4 B). This is performed for all 20 mass 
spectra of the sample set, which all display different intensities of the 3 same signals (Fig. 
1.1.4 C). In general, a set of mass spectra containing n distinct signals can be projected in an 
n-dimensional space, which features n so called principle components (PC) as the basis for a 
novel coordinate system (Fig. 1.1.4 D). The PCs are placed into the old coordinate system 
according to the following rules [55]: 
 The center of the datapoints is the origin of the new coordinate system 
 The first PC is placed in the direction of the highest variance. The second PC is placed 
in the direction of the second highest variance and so on. 
 The coordinates are perpendicular 
                                               
3 Example adapted from: BRUKER - MALDI Imaging tutorial PCA intro, © Bruker 2010 
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The variance plot describes which fraction of the data set’s variance is covered by the 
respective PC (Fig. 1.1.4 E). By excluding low variance PCs, the dataset is projected into a 
lower dimensional space while retaining most of the dataset’s variance (Fig. 1.1.4 F).  
 
 
Figure 1.1.4: Dimensionality reduction using PCA. A) Illustration of a mass spectrum 
consisting of 3 signals. B) Vectorized illustration in 3D space of spectrum displayed in (A). C) 
Vectorized illustration in 3D space of 20 sample mass spectra. D) Graph displayed in (C) with 
PCs as novel coordinates. E) Variance plot, displaying the variance covered by the PCs 
displayed in (D). F) Graph displayed in (D) upon reduction of PC3. (Example adapted with 
some modifications from: BRUKER - MALDI Imaging tutorial PCA intro, © Bruker 2010) 
 
In the end PCA illustrates how similar spectra are [56]. Groups of spectra that form more 
condensed “clouds” are more similar, whereas the distance between spectra or groups of 
spectra is a measure for spectral differences. 
Since some signals expose greater variance than others, not all signals contribute equally to 
the placement of the PCs. Therefore, an additional, interesting piece of information is to which 
extend a certain signal contributed to the variance covered by a certain PC. In other words: 
“Which signals contributed most to separate my data along the PC1 axis?” This information is 
displayed in the loadings plot [56]. 
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1.2 DRUG DISCOVERY 
 
Drug discovery is the process, which aims to find preclinical candidates for novel 
medications. At the end of discovery, preclinical candidate leads are selected and progressed 
into preclinical development. The output of a successful preclinical development is an 
investigational new drug (IND) application which includes information on animal 
pharmacology and toxicology studies, manufacturing information and clinical investigator 
guidance. The IND is required to start clinical trials. The result of successful clinical 
development is the filing of a new drug application (NDA), which requests the food and drug 
administration to approve the market entry of a new drug in the United States. The NDA 
includes information for FDA reviewers on the drug’s safety, proposed use, appropriate 
labelling and manufacturing4. In contrast to drug discovery, clinical development is highly 
regulated by requirements like good clinical practice (GCP) and good manufacturing 
practice (GMP). 
A key process in drug discovery is the identification of lead compounds. These are 
compounds that possess pharmacological activity and could become therapeutically useful 
upon structural optimization. As a first step, hit compounds are identified by high throughput 
screening (HTS) [57]. During a HTS campaign, pharmaceutical companies test compound 
libraries, which contain typically more than 50.000 and up to millions of compounds [58]. HTS 
is driven by a high degree of automation and has been established in the early 90th. The past 
three decades were dominated by target-based drug discovery (TDD), where a presumably 
disease relevant molecular target was the starting point of screening campaigns [59]. In recent 
years, interest in phenotypic drug discovery (PDD), in which the molecular drug target is 
unknown, was revived by studies highlighting PDD’s strong contribution to the past discovery 
of first in class drugs [59, 60]. 
In vitro assays used for drug discovery can be differentiated between biochemical assays and 
cell-based assays. For biochemical assays, the compounds are tested in a reaction mixture 
containing the purified protein drug target and all relevant substrates. For mechanistic cell 
assays the drug target is also known and the assay readout is directly linked to the cellular 
target activity. Mechanistic cell assays are important for drug discovery in pharmaceutical 
industry. There are numerous examples in the literature of biochemical enzyme assays and 
mechanistic assays going hand in hand to measure the cellular activity of inhibitors [61, 62]. 
Phenotypic cell assays can be of help when the complexity of a disease is not completely 
                                               
4 Investigational New Drug (IND) Application - Drug Development and Review Definitions. Available at: 
https://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approva
lapplications/investigationalnewdrugindapplication/ucm176522.htm.  
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understood or a mechanistic readout is not accessible. In this case, changes of the cellular 
morphology or molecular signatures are potential assay readouts [59]. 
Upon their identification, screening hits are confirmed by approaches like counter-screens, 
orthogonal assays or computational approaches [63]. Confirmed hit compounds are optimized 
in a process called hit-to-lead expansion. Lead compounds are improved by medicinal 
chemists in a synthetic effort to optimize biologic activity towards one or several candidate 
compounds for clinical trials. These optimizations may include modifications of lipophilicity, 
binding efficiency and molecular weight [64]. The chemical space is estimated to theoretically 
harbor 1030 – 1060 drug like molecules, enabling a vast variety of options to optimize the 
screening hit. The final clinical candidate often constitutes a compromise between biological 
activity and ADMET (absorption, distribution, metabolism, excretion and toxicity) properties 
[65]. 
Presently, clinical development and approval of a new drug requires extensive resources and 
can cost up to a billion dollars. Therefore, a thorough characterization of novel compounds in 
the early discovery stage is vital for the pharmaceutical industry [66]. Over the past 60 years, 
advances in combinatorial chemistry considerably increased the size of compound libraries. 
Increased speed of DNA sequencing by orders of magnitude facilitated the discovery of novel 
potential drug targets. Databases with protein structures facilitate structure guided lead 
improvement. Nevertheless, the number of new drugs brought to the market per billion US 
dollar spent on R&D has constantly declined over the past 50 years [67]. This trend indicates 
a declining efficiency of pharmaceutical R&D and is presumably not answered by further 
increasing budgets spend on R&D. In recent years, there is a growing tendency for 
pharmaceutical companies to outsource the early phase of drug research and discovery to 
contract research organizations (CROs) [68]. The market-research publisher Kalorama 
predicted that by 2021 more than one third of drug discovery worldwide will be outsourced to 
CROs5. 
 
1.2.1 RATIONALE FOR METABOLITE-BASED MALDI MS TO SUPPORT CELL-BASED ASSAYS IN DRUG 
DISCOVERY 
 
Historically, the most widespread application of cell-based assays was to evaluate cell death. 
Since in vitro cytotoxicity assays have been found to not be very predictive for in vivo toxicity 
                                               
5 Kalorama Information: Outsourced Drug Discovery Market Boosted by Gap in Pipelines. Available at: 
https://www.kaloramainformation.com/about/release.asp?id=4326. 
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[69], cytotoxicity assays are mainly used as controls for other cell-based assays. These assays 
evaluate biological activity, biochemical mechanisms, and off-target effects [66]. Moreover, 
cell-based assays are used for HTS due to their complaisance to multiplexing [70] and 
miniaturization down to the single cell level [71]. 
Fluorescence-based readouts are most widely used in both biochemical and cellular drug 
discovery assays [72]. Compared to biochemical screenings, cell-based assays do not require 
confirmation that the compound is cell-permeable and is still active in its destined compartment 
in the presence of competing small molecules. For example, GSK performed an in vitro 
screening campaign against the full-length, recombinant fatty acid synthase, purified from 
insect cells. The hit-compound GSK837149A turned out to have impaired cell penetration [73]. 
Still fluorescence, as well as other label-dependent cell assays, require extensive validation, 
due to photonic artefacts including autofluorescence of the compound, spectral overlap of 
compound and fluorophore as well as quenching of the fluorescence or bleaching of the 
fluorophore6. Transfection of engineered cells and interferences of reporter constructs can lead 
to a distortion of cellular physiology that diminishes data reliability [74]. The emergence of 
label-free platforms aspires to overcome these limitations by providing readouts that do not 
interfere with biological function. Major classes of label-free systems for cell-based 
investigations besides mass spectrometry include refraction index and cell impedance. 
Refraction index is employed to monitor binding properties of drug candidates and cell 
impedance could be used to monitor physiologic events such as cell attachment, migration or 
apoptosis [74, 75]. MS technologies are especially amenable for targeted investigations of 
mass changes, like enzyme reactions [75]. 
Liquid chromatography (LC) MS is a sensitive method that can quantitatively monitor a broad 
range of drug actions without any labeling reagents. A major limitation of LC-MS is the 
method’s throughput. With durations of ~4h per 96-well plate, LC-MS is suitable for medium 
throughput screens rather than high-throughput primary screens [58, 76]. 
Automated MALDI-TOF cell assays, as a fast, sensitive and rather impurity tolerant approach, 
could be a cost effective alternative to existing label-dependent methods. The label-free 
MALDI-TOF readout saves expensive detection kits, but purified proteins and antibodies are 
required for biochemical assays. Additionally, low sample volumes of ≤2µl per measuring spot 
are compatible with current HTS standards [77]. 
MALDI-TOF MS has already proven to be a valuable tool to screen inhibitors of 
pharmacologically relevant targets in biochemical assays. These targets included various 
                                               
6 Simeonov A, Davis MI (2004) Interference with Fluorescence and Absorbance. Eli Lilly & Company 
and the National Center for Advancing Translational Sciences 
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kinases [77–79], the histone demethylase JMJD2c [80], the tyrosine phosphatase PTP1B [57] 
and several human deubiquitinases [81]. 
Also protein-based IC-MALDI MS assays have been suggested as relevant tools to support 
drug discovery. Especially noteworthy is the aforementioned cell-assay developed by 
Munteanu et al. that enables label-free monitoring of histone deacetylase inhibition [29]. Due 
to protein modification turnover rates of only seconds, monitoring of protein modifications, as 
in the Munteanu et al. publication, is a sensitive and fast methodology. On the other hand, 
choosing protein levels as response markers for inhibitor treatment might be unfavorable, since 
protein turnover in mammalian cells can take up to several hours [82]. In comparison, 
metabolites, especially metabolites containing reactive phosphate groups, have been 
described to be turned over within seconds or fractions of a second [83]. Therefore, monitoring 
of metabolites harbors the expectation to dramatically increase the sensitivity and dynamic 
range MALDI MS cell assays. 
Moreover, establishment of protein-based MALDI-TOF cell assays requires extensive work to 
identify the response biomarker by top-down proteomics. This is expected to be less tedious 
for metabolite-based assays where the signal can be validated by structural elucidation using 
high resolution mass determination and MS/MS fragmentation analysis [84]. 
Additionally, with its unique strengths MALDI-TOF MS is anticipated to tackle a problem called 
“screening the unscreenable”. For example, the dihydroceramide desaturase 1 (DEGS1) is 
a multiple membrane-spanning protein located in the ER which catalyzes the final step of de 
novo ceramide synthesis. DEGS1 is a therapeutic target for metabolic diseases since it has 
been described to regulate ceramide induced lipotoxicity [85] and to simultaneously stimulate 
anabolic and catabolic signaling [86]. Despite its potential therapeutic relevance DEGS1 is 
notoriously difficult to screen. As an enzyme that requires its transmembrane domains for 
catalytic activity, the protein is particular difficult to purify and therefore hardly accessible for 
cell-free in vitro screens. The same holds true for additional transmembrane enzymes like the 
stearoyl-CoA desaturase SCD1, which catalyzes the formation of monounsaturated fatty acids. 
Regulation of SCD1 activity has been known to affect susceptibility of several diseases 
including obesity, insulin resistance and diabetes [87]. These targets require analysis in a more 
physiological, ideally cellular, context. 
Ordóñez-Gutiérrez et al. determined DEGS1 activity in cellular lysates by adding a fluorescent 
substrate. The suspension was analyzed by HPLC coupled to a fluorescence detector [88]. Li 
et al. measured the stearoyl-CoA to oleoyl-CoA ratio in mouse hepatocytes upon knock out of 
an SCD1 regulating protein by LC-MS [89]. Roemeling et al. isolated SCD1 containing 
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microsomes from murine liver. The in vitro biotransformation of 13C18-stearoyl-CoA to 13C18-
oleoyl-CoA was monitored by LC-MS [90].  
To date, no HTS-compatible analysis has been described to analyze the activity of either of 
these enzymes. Therefore, especially metabolic transmembrane enzymes are a challenging 
but reasonable target for metabolite-based MALDI MS cell assays. A fundamental step would 
be to prove that metabolite-based MALDI MS cell assays are feasible.  
 
1.2.2 IMATINIB – THE FIRST FDA-APPROVED TYROSINE KINASE INHIBITOR – AND OTHER BCR-ABL 
INHIBITORS 
 
Chronic myeloid leukemia (CML) is a leukemia that is characterized by an upregulated 
proliferation of myeloid cells in the bone marrow. CML accounts for about 15 % of newly 
diagnosed leukemias in adults [91]. 
A unique gene translocation known as the Philadelphia chromosome is the most frequent 
cause of CML. The Philadelphia chromosome is an oncogenic fusion of the breakpoint cluster 
region (BCR) which is localized on chromosome 22 and the abl gene from chromosome 9 (Fig. 
1.2.1). The resulting gene product is a continuously active tyrosine kinase that promotes cell 
proliferation and inhibits DNA repair [92]. 
Due to difficulties to identify molecular components downstream of BCR-Abl, the tyrosine 
kinase itself is the most relevant target for drug discovery [93]. The first orally available and 
potent BCR-Abl tyrosine kinase inhibitors were discovered using a targeted approach in the 
late 1980s by the famous scientist Brian Druker at Ciba Geigy, today part of Novartis [93]. The 
lead compound was based on a hit from a screen of inhibitors against protein kinase C [94]. 
Lead optimization resulted in the promising candidate, imatinib mesylate, which entered clinical 
trials in 1998 [93, 94]. 
On the 18th month of phase 3 clinical trials, CML patients treated with imatinib showed 76.2 % 
complete cytogenetic response (0 % BCR-Abl+ cells) compared to 14.5 % in the interferon 
alpha plus cytarabin-treated group [95]. Due to the dramatic benefit of imatinib between 
groups, the comparison-clinical trials were aborted and the interferon alpha plus cytarabine-
treated group crossed over to the imatinib treated group, shifting the focus to an in-depth 
understanding of imatinib treatment [95].  
The tyrosine kinase inhibitor Imatinib has revolutionized the therapy of not only of CML but 
also malignancies related to KIT and PDGFRA mutations. Activating mutations of the receptor 
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tyrosine kinases KIT and PDGFRA are especially associated with gastrointestinal stromal 
tumors [96]. Moreover, activating KIT mutations are known to cause sporadic adult human 
mastocytosis [97].  
Although survival rates of BCR-Abl+ patients dramatically increase upon imatinib 
administration, a number of mechanisms by which resistance to imatinib arises have been 
described. These include mutations in the ABL-kinase domain, amplification of BCR-Abl and 
the overexpression of the multidrug-resistance transporter, P-glycoprotein [98]. 
The limitations of imatinib inspired the development of more potent second generation tyrosine 
kinase inhibitors like nilotinib and dasatinib [99]. Imatinib, as well as its FDA approved second 
generation inhibitors, are ATP competitive, catalytic-side ABL1 inhibitors. Discovery of novel 
pharmaceuticals for dual inhibition of BCR-Abl has become increasingly interesting in recent 
years [100]. One fascinating strategy is to target the myristate-pocket of BCR-Abl. The intact 
Abl kinase contains a myristoylated cap region that induces an autoinhibitory conformational 
change [101]. Even though the myristoylated cap region has been replaced by the truncated 
BCR protein, the myristate-pocket remained in the BCR-Abl fusion protein. The non-ATP 
competitive inhibitor ABL001 mimics myristate binding and was shown to be antiproliferative 
at submicromolar concentrations in preclinical studies, using BCR-Abl+ cell lines [100]. 
ABL001 is currently being tested in a phase I, multicenter, open-label study. 
In 2015, Breitkopf et al. published a study on the effect of imatinib treatment on BCR-Abl+ 
H929 multiple myeloma cells, which were analyzed by a combination of metabolomics, 
lipidomics, and phosphoproteomics approaches [102]. The triomics study presents evidence 
that imatinib globally induces lipidome changes which is primarily mediated through signaling 
of the BCR-Abl-ERK pathway [102].  
Due to the multitude of reported lipidomic changes, monitoring of BCR-Abl inhibition is 
expected to be a relevant example for the application of a small molecule-based MALDI MS 
biotyping workflow. 
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Figure 1.2.1: Formation of the Philadelphia chromosome by reciprocal translocation. 
 
1.2.3 FATTY ACID SYNTHASE AS A DRUG TARGET 
 
Fatty acid synthase (FASN) is a multi-enzyme protein that catalyzes the formation of the fatty 
acid palmitate, which is formed in an NADPH dependent condensation of acetyl-CoA and 
malonyl-CoA: 
Acetyl-CoA + 7 Malonyl-CoA + 14 NADPH  
Palmitate + 14 NADP+ + 7 CO2 + 8 CoA 
The growing fatty acid chain is formed by an iterative action of a ketoreductase (KR), a 
dehydratase (DH) and enoyl reductase (ER) (Fig. 1.2.2).  
FASN is a key enzyme in the lipid metabolism, which has been associated with a variety of 
diseases including cancer [103], diabetes [104], cardiovascular [105] and neurodegenerative 
diseases [106]. 
FASN overexpression has been described in many hematopoietic and solid tumors, including 
lung, colon, prostate and breast cancer. Moreover, overexpression of FASN in human 
carcinomas is associated with a poor prognosis and resistance to cancer therapy [107]. 
Ventura et al. showed anti-tumor activity of FASN inhibition using in vitro and in vivo models 
of human cancer [107]. FASN inhibition causes tumor apoptosis by multiple mechanisms, 
including reprogramming of gene expression, inhibition of signaling pathways, and remodeling 
of cell membranes. 
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A HTS strategy, using the full length recombinant, human FASN in a biochemical assay, to 
identify FASN inhibitors has been published by GSK [73, 108]. Vazquez et al. performed a 
biochemical NADPH consumption assay with a resorufin-based fluorescence readout. NADPH 
itself is UV absorbent. Yet, measuring its absorbance is poorly sensitive and interferes with 
too many compounds. Resorufin is sensitive to quenching by the nucleotides NADH and 
NADPH. In batches containing potent FASN inhibitors, little NADPH is consumed by the 
enzymatic reaction. Due to quenching of resorufin a weak fluorescent signal is obtained for hit 
compounds. 
One screening hit was the aforementioned GSK837149A, an inhibitor of the 3-ketoacyl 
reductase domain of the FASN, which is apparently not cell-permeable [73]. Another hit 
compound was GSK2194069, a potent (pIC50 = 7.7 nM, biochemical assay), cell-permeable 
inhibitor which also targets the 3-ketoacyl reductase domain of the FASN [109]. Fasnall is a 
potent FASN inhibitor (pIC50 = 147 nM, cellular assay) discovered at Duke University School 
of Medicine in a chemoproteomics screen where compounds were tested for the release of 
protein extracts bound to cibacron blue sepharose beads upon exposure to a compound 
library. The used protein extracts were obtained from porcine lactating mammary glands, which 
are a rich source of FASN [110]. It is worth mentioning that the authors provided no information 
on cofactor competition or the inhibited target domain. A summary of latest generation, 
preclinical FASN inhibitors, all displaying at least a nanomolar IC50 in a biochemical or cellular 
FASN assay, is provided in table 1.2.1. The majority of FASN inhibitors have failed to advance 
into development. Presently, the only FASN inhibitor that has advanced to a clinical trial is 3V 
Biosciences’ TVB-2640, which is currently not commercially available. TVB-2640 is tested for 
treatment of solid tumors [110, 111]. This chapter elaborates that presently available FASN 
assays are indirect, unprecise and time consuming, which highlights the need for the 
development of advanced assays. 
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Table 1.2.1: Selected, preclinical FASN inhibitors. 
Compound, 
Sponsor 
assay for hit 
identification 
IC50 
[nM] 
assay for IC50 determination Ref. 
TVB-3166, 3-V 
Biosciences 
undisclosed 60 Cell assay of palmitate generation from 13C-
acetate using human cervical cancer HeLa 
cells; saponified extracts analyzed by triple 
quad LC-MS. 
[107] 
BI 99179, 
Boehringer 
Ingelheim 
undisclosed 600 Cell assay: Mouse hypothalamic N-42 cells 
incubated with compound for 1h, 14C-acetate 
in Krebs-Ringer-buffer incubation for 4h, 
methanol/chloroform (1/1) extraction, 
measurement in ß-counter. 
[112] 
79 Biochemical assay: NADPH consumption 
using FASN isolated from Hela cells 
(undisclosed purification strategy), 
photometric detection of NADPH at 340 nm. 
Fasnall, Duke 
University 
Chemoproteomic 
screen: Release of 
proteins bound to 
cibacron blue 
sepharose upon 
exposure to 
compound library. 
147 Cellular assay: Human liver cancer HepG2 
cells incubated in 3H-acetate medium and 
compound for 1 h, lysates were subjected to 
liquid scintillation counting. 
[110] 
3710 Biochemical assay: human FASN 
(undisclosed source and purification strategy) 
was pre-incubated with Fasnall, addition of 
substrates acetyl-CoA, NADPH and malonyl-
CoA spiked with 2-[14C]malonyl- CoA for 30 
min, chloroform/methanol (2/1) extraction, 
measurement by liquid scintillation counting. 
GSK2194069, 
GlaxoSmith-
Kline 
Biochemical FASN 
assay: Monitoring of 
NADPH 
consumption using 
full length 
recombinant 
hFASN, 
photometric 
detection of NADPH 
induced quenching 
of resorufin. 
7.7 
 
Biochemical assay using full length 
recombinant, human FASN expressed in Sf9 
insect cells: Detection of CoA production 
using thio-reactive coumarin dye CPM, 
fluorescent readout using 380 nm excitation 
wavelength filter, and 486 nm emission filter. 
[109] 
15 Cellular phospholipid assay: A549 cells 
treated for 48 h, phospholipids were 
measured in an enzyme-coupled reaction 
using PC-specific phospholipase D and 
choline-oxidase. Reaction product H2O2 was 
detected using Amplex Red fluorogenic 
substrate reactoin, fluorescent readout at 560 
nm. 
JNJ-
54302833, 
Johnson & 
Johnson 
undisclosed 28 Biochemical assay using full length 
recombinant, human FASN expressed in 
insect cells: 3H-acetyl-CoA and malonyl-CoA 
were used as substrates. Product 3H-
palmitate binds to hydrophobic scintillation 
proximity assay imaging beads. Emitted light 
is measured using a 610 nm pass filter.  
[113] 
Platensimycin, 
Merck 
Same principle as 
for IC50 
determination. 
 
300 Biochemical assay using human FASN 
purified by ammonium sulfate fractionation 
and ion-exchange chromatography from 
human cell lines (SKBr3 and HepG2): 
Detection of CoA production using thio-
reactive coumarin dye CPM, fluorescent 
readout using 380 nm excitation wavelength 
filter, and 486 nm emission filter. 
[114] 
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Figure 1.2.2: The enzymatic reactions of the fatty acid synthase. Malonyl-CoA is 
composed from acetyl-CoA and CO2 by the enzyme acetyl-CoA carboxylase. 6 distinct 
enzymatic domains, highlighted in grey, of the FASN are involved in the formation of palmitate. 
The growing fatty acid chain is linked to and shuttled between the enzymatic domains by a 
phosphopantetheine prosthetic group, “Pan”, of an acyl carrier protein. The enzymatic reaction 
is initiated by the acetyl transacetylase. Palmitate is formed in 7 consecutive cycles of 3-
ketoacyl synthase, 3-ketoacyl synthase, hydratase and enoyl reductase which is released by 
the thioesterase domain.  
- 24 - 
2 AIMS 
 
MALDI MS is a sensitive and a rather impurity tolerant method. Technological advances 
increased measurement speed to less than a second per data point. The implementation of 
MALDI MS in vitro assays has advanced the repertoire of targets that can be screened by label 
free, high throughput technology. The limitations of MALDI MS in vitro biochemical assays are 
the restricted availability of purified drug targets, as well as the poor predictability of a screening 
hit’s action in a more physiologic, cellular environment. Moreover, established protein-based 
MALDI MS cell assays are limited by a complicated identification of the underlying protein 
marker molecules, and a small dynamic range of the assay readout. Cellular metabolites 
harbor the potential to display a greater dynamic range compared to proteins. Additionally, 
identification and validation of metabolite marker molecules is potentially much easier with 
FTMS technology. In conclusion, metabolite-based MALDI MS cell assays might open up a 
completely new avenue for drug discovery. 
Therefore, this thesis is focused on the following objectives: 
 Development of a MALDI MS workflow that enables sensitive and reproducible 
acquisition of metabolite spectra from whole cells. 
 
 Incorporation of the developed MALDI MS workflow into pharmacologically relevant 
assays. 
 
 Discovery of metabolite drug response markers by MALDI-TOF MS and their 
identification/validation by MALDI-FTICR MS/MS. 
 
 Evaluation of the utility of these workflows for standardized metabolite-based MALDI 
MS cell drug assays. It was intended to evaluate examples for MALDI MS-based 
phenotypic as well as mechanistic cell assays. 
 
 Automation of the established assays by evaluating and developing both novel 
technologies and software solutions. 
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3 MATERIALS AND METHODS 
 
3.1 MATERIALS 
 
3.1.1 CHEMICALS 
 
3.1.1.1 GENERAL CHEMICALS 
 
Chemical Company (Headquarter) Catalogue number 
Acetone VWR International (Darmstadt, 
GER) 
1.00012 
Acetonitrile VWR International (Darmstadt, 
GER) 
1.00030 
Benzoic acid Sigma Aldrich (Munich, GER) 242381 
Bovine serum albumin Applichem (Darmstadt, GER) A1391 
5x Bradford reagent Bio-Rad (München, GER) 5000006 
Ethanol absolute VWR International (Darmstadt, 
GER) 
20825 
Glycerol Sigma Aldrich (Munich, GER) G9012 
Hexane VWR International (Darmstadt, 
GER) 
83992.320 
Methanol VWR International (Darmstadt, 
GER) 
83638.320 
Milli-Q water Prepared in-house  
Nitrocellulose Sigma Aldrich (Munich, GER) 88018 
Peptide Calibration 
Standard II 
Bruker Daltonics (Bremen, GER) 8222570 
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Propan-2-ol VWR International (Darmstadt, 
GER) 
1.09634 
 
3.1.1.2 CHEMICALS FOR CELL CULTURE  
 
Chemical Company (Headquarter)  Catalogue number 
D(+)Glucose Applichem (Darmstadt, GER) A1422 
DMSO VWR International (Darmstadt, 
GER) 
A3672 
FCS Life Technologies (Darmstadt, 
GER) 
10270 
FCS, charcoal stripped Life Technologies (Darmstadt, 
GER) 
F6765 
HEPES Applichem (Darmstadt, GER) A1069 
IMDM VWR International (Darmstadt, 
GER) 
L0190 
L-Glutamine Sigma Aldrich (Munich, GER) G7513 
PBS Sigma Aldrich (Munich, GER) P3744 
PEN/STREP Life Technologies (Darmstadt, 
GER) 
15140122 
RPMI VWR International (Darmstadt, 
GER) 
L0498-500P 
Sodium pyruvate Sigma Aldrich (Munich, GER) S8636 
Trypan blue Sigma Aldrich (Munich, GER) T8154 
Trypsin/EDTA Sigma Aldrich (Munich, GER) T4049 
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3.1.1.3 COMPOUNDS FOR CELL CULTURE TREATMENT 
 
Compound Company (Headquarter) Catalogue number 
BI 99179 Boehringer Ingelheim 
(Ingelheim, GER) 
not commercially 
available7 
BI 99990 Boehringer Ingelheim 
(Ingelheim, GER) 
Chloroquine diphosphate 
salt 
Sigma Aldrich (Munich, GER) C6628 
Dasatinib LC Laboratories (Woburn, USA) D-3307 
Imatinib LC Laboratories (Woburn, USA) I-5577 
GSK2194069 Sigma Aldrich (Munich, GER) SML1259 
GSK837149A Sigma Aldrich (Munich, GER) G5547 
Nilotinib LC Laboratories (Woburn, USA) N-8207 
Orlistat Sigma Aldrich (Munich, GER) O4139 
Sunitinib malate salt LC Laboratories (Woburn, USA) S-8803 
Triclosan VWR International (Darmstadt, 
GER) 
L18655 
TOFA VWR International (Darmstadt, 
GER) 
10005263 
Vandetanib LC Laboratories (Woburn, USA) V-9402 
  
                                               
7 Compounds were kindly shared by Boehringer Ingelheim’s platform to access preclinical molecules for 
research (www.opnMe.com). 
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3.1.1.4 CHEMICALS FOR MATRIX PREPARATION 
 
Chemical Company (Headquarter) Catalogue number 
ATT (6-aza-2-thiothymine) Sigma Aldrich (Munich, GER) 275514 
DHB (2,5-Dihydroxybenzoic 
acid) 
Bruker Daltonics (Bremen, 
GER) 
8201346 
Trifluoroacetic acid Merck (Darmstadt, Germany) 1082620025 
 
3.1.1.5 CALIBRATION COMPOUNDS AND STANDARDS 
 
Calibrant / Standard Company (Headquarter) Catalogue number 
Malonyl-CoA Sigma Aldrich (Munich, GER) M4263 
Malonyl-13C3-CoA Sigma Aldrich (Munich, GER) 655759 
Olanzapine SelleckChem (Houston, USA) S2493 
Peptide calibration standard 
II 
Bruker Daltonics (Bremen, 
GER) 
8222570 
Romidepsin SelleckChem (Houston, USA) S3020 
Sorafinib Free Base LC Laboratories (Woburn, 
USA) 
S-8599 
  
- 29 - 
3.1.2 CONSUMABLES 
 
Consumable Company (Headquarter)  Catalogue number 
Cell culture plates with 6 / 24 
/ 96-wells  
Greiner bio-one (Solingen, 
GER) 
M8562 / M8812 / M0812 
Centrifuge tubes 0.5 / 1.5 / 2 
ml 
Eppendorf (Hamburg, GER) 0030121023 / 
0030120086 / 
0030120094 
Centrifuge Tubes 15 / 50 ml VWR International (Darmstadt, 
GER) 
525-0150 / 525-0155 
MALDI 384 ground steel 
target 
Bruker Daltonics (Bremen, 
GER) 
8280784 
Neubauer Improver VWR International (Darmstadt, 
GER) 
631-0696 
Nitrile examination gloves VWR International (Darmstadt, 
GER) 
112-4513 
Pipet Tips 10/200/1000 µl VWR International (Darmstadt, 
GER) 
613-0576 / 613-0579 / 
613-0582 
Serological pipettes 10 / 25 
ml 
VWR International (Darmstadt, 
GER) 
612-3700DE / 612-
3698DE 
T75 cell culture flasks for 
adherent / suspension 
culture 
Greiner bio-one Solingen, GER C7231-120EA / C6731-
200EA 
CyBio® RoboTipTray 96/60 
μl 
Analytik Jena (Jena, GER) OL3810-25-441 
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3.1.3 EQUIPMENT AND INSTRUMENTS 
 
Equipment / Instrument Model, Company (Headquarter) 
Centrifuges Heraeus Fresco 21, Thermo Fisher Scientific 
(Schwerte, GER) 
SIGMA 6K15, Sigma  Laborzentrifugen GmbH 
(Osterode, GER) 
Balances Analytical Balance Sartorius Research R200D, 
Sartorius (Göttingen, GER) 
Clean Bench AireGard ES NU-140 Vertical Laminar Airflow 
Workstation, Nuaire (Caerphilly, UK) 
Cell Culture Incubator Heracell 150, Thermo Fisher Scientific (Schwerte, 
GER) 
Mass spectrometers autoflex speed MALDI-TOF/TOF, Bruker Daltonics 
(Bremen, GER) 
solariX 7T XR FTICR, Bruker Daltonics (Bremen, GER) 
ultrafleXtreme MALDI-TOF/TOF, Bruker Daltonics 
(Bremen, GER)  
rapifleX MALDI-TOF, Bruker Daltonics (Bremen, GER) 
Matrix spray device Sun Collect Sprayer, SunChrom (Friedrichsdorf. GER) 
HTX TM-Sprayer, HTX Technologies (Chapel Hill, 
North Carolina, USA) 
Microscope Invert light microscope AE 31, Motic (Wetzlar, GER) 
Pipettes 10/100/1000 µl Eppendorf Research plus, Eppendorf (Hamburg, GER) 
Pipetting Platform CyBio FeliX, Head R 96/60 µl, Analytik Jena (Jena, 
GER) 
Plate reader Multiscan Spectrum, Thermo Fisher Scientific 
(Schwerte, GER) 
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3.1.4 HUMAN CELL LINES 
 
Cell Line Origin Culture 
Properties 
Provider 
A549 Lung carcinoma Adherent Merck (Darmstadt, 
GER) 
GIST-T1 GIST Adherent EU-MITIGATE 
consortium 
HL-60 ALL Suspension ATCC (Manassas, 
USA) 
K562 CML Suspension CLS (Eppelheim, 
GER) 
 
3.1.5 SOFTWARE FOR DATA ACQUISITION 
 
Name Instrument Company 
flexControl 3.4 autoflex speed and 
ultrafleXtreme MALDI-
TOF/TOF 
Bruker (Bremen, GER) 
flexControl 4.0 rapifleX MALDI-TOF Bruker (Bremen, GER) 
ftmsControl 2.1.0 solariX 7T XR FTICR Bruker (Bremen, GER) 
 
Sonic bath VWR International 
Vacuum Aspirator Vacusafe, Integra (Zizwers, CH) 
Water purification system EMD Millipore™ Milli-Q™ Reference Ultrapure Water 
Purification System, Thermo Fisher Scientific 
(Schwerte, GER) 
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3.1.6 SOFTWARE FOR DATA ANALYSIS, VISUALIZATION AND CHEMICAL DRAWING 
 
Name Company (Headquarter) 
ChemSketch ACD Systems (Toronto, CAN) 
ClinProTools 3.0 Bruker (Bremen, GER) 
DataAnalysis 4.4 Bruker (Bremen, GER) 
flexAnalysis 3.4 Bruker (Bremen, GER) 
Microsoft Visio Microsoft (Redmond, USA) 
Microsoft Powerpoint Microsoft (Redmond, USA) 
R Studio RStudio Team (Boston, USA) 
R 3.3.1 R Foundation for Statistical Computing (Vienna, AUT) 
Prism 5 GraphPad Software (California, USA) 
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3.2 METHODS 
 
3.2.1 CULTIVATION OF HUMAN CELL LINES 
 
3.2.1.1 CULTIVATION OF A549 AND GIST-T1 ADHERENT CELL LINES 
 
A549 and GIST-T1 cells were cultured at 37 °C, 5 % CO2 and 95 % humidity in supplemented 
RPMI-1640 or IMDM respectively. Cells were grown to 70 % confluency in T75 flasks. To split, 
a T75 flask was washed with 2 ml trypsin buffer prior to incubation with 2 ml trypsin buffer for 
5 mins. Cells were resuspended in 8 ml of fresh medium and split into a new maintaining flask. 
A maintaining flask was seeded at 10 - 20 % confluency. 
 
Supplements added to RPMI-1640 for A549 cultivation 
10 %  FBS 
2 mM Glutamine 
120 µg Penicillin / Streptomycin 
 
Supplements added to IMDM for GIST-T1 cultivation 
15 %  FBS 
2 mM Glutamine 
120 µg Penicillin / Streptomycin 
 
  
- 34 - 
3.2.1.2 CULTIVATION OF HL60 AND K562 SUSPENSION CELL LINES 
 
HL60 and K562 cells were cultured at 37 °C, 5 % CO2 and 95 % humidity in supplemented 
IMDM or RPMI-1640, respectively. The cell density was determined by applying 10 µl of 
suspension to a Neubauer counting chamber (hemocytometer). The cultures were split when 
cultures reached a density of 1 - 2 ∙ 106 cells / ml. A new maintaining flask was seeded at 0.1 
- 0.2 ∙ 106 cells / ml, by transferring the needed amount of culture to a new flask and adding 
fresh media. 
 
Supplements added to IMDM for HL60 cultivation 
20 %  FBS 
4 mM Glutamine 
120 µg Penicillin / Streptomycin 
 
Supplements added to RPMI-1640 for K562 cultivation 
10 %  FBS 
2 mM Glutamine 
1 mM Sodium pyruvate 
10 mM HEPES 
1.25 g Glucose 
120 µg Penicillin / Streptomycin 
 
3.2.1.3 CELL HARVEST FOR MALDI METHOD DEVELOPMENT  
 
Trypsinized, adherent cells or suspension culture cells were pelleted by centrifugation for 5 
min at 800 rpm and 4 °C. The pellet was resuspended in ice cold PBS and pelleted again. The 
pellet was resuspended in PBS a second time. A 10 µl aliquot was mixed with Trypan Blue 
and applied to a Neubauer counting chamber to determine the cell density and viability. 
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Cell aliquots containing 106 cells each were transferred to Eppendorf cups and centrifuged at 
2,000 rpm for 5 min at 4 °C on a benchtop centrifuge. Supernatants were removed using a 
vacuum aspirator. The pellets were snap-frozen and stored at -80 °C until further use. 
 
3.2.1.4 CELL PELLET GENERATION FOR CELL DRUG ASSAYS 
 
1 day prior to inhibitor treatment K562 cells were resuspended at 0.25 x 106 cells / ml in assay 
medium. 1 ml of the suspension was added to each well of a 24-well plate. Except for 
chloroquine, all inhibitors were dissolved in DMSO to a final concentration of 30 mM. 
Chloroquine was dissolved in H2O to a final concentration of 30 mM. On the day of inhibitor 
treatment, dilution series of the inhibitors were prepared in a 12-step dilution series and 1 µl 
inhibitor was added to 1 ml culture. After 6, 12, 24 or 48 h, cells were transferred to Eppendorf 
tubes and pelleted at 2,000 rpm for 5 min at 4 °C using a benchtop centrifuge. Supernatants 
were removed using a multi-channel vacuum aspirator. The pellets were snap-frozen and 
stored at -80 °C until further use. 
 
Tyrosine-kinase inhibitor assay medium 
500 ml RPMI-1640 
10 %  FBS 
2 mM Glutamine 
1 mM Sodium pyruvate 
10 mM HEPES 
1.25 g Glucose 
120 µg Penicillin / Streptomycin 
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FASN assay medium 
500 ml RPMI-1640  
2 mM L-Glutamine 
10 % FCS, charcoal stripped 
 
3.2.1.5 CELL PELLET GENERATION FOR AUTOMATED CELL DRUG ASSAYS 
 
1 day prior to inhibitor treatment, cells were resuspended at 0.25 x 106 cells / ml (K562 cells) 
or 0.1 x 106 cells / ml (A549 cells) in FASN assay medium. 200 µl of the suspension were 
added to each well of a 96-well “culture-plate”. All inhibitors were dissolved in 40 µl DMSO and 
transferred to a new 96-well “compound-plate”. On the day of inhibitor treatment, 1 µl inhibitor 
were transferred from the 96-well compound plate to the 96-well cell culture plate using the 
CyBio FeliX pipetting platform. For that purpose, the pipetting platform was equipped with a 
96-well 60 µl tip tray, aspirated 10 µl from the cavities of the compound plate and released 1 
µl in the cavities of the culture plate. The remaining liquid was disposed into a waste bucket. 
After 24 h, whole 96-well culture plates were centrifuged at 800 rpm for 5 min using a SIGMA 
6K15 centrifuge. Supernatants were removed using a vacuum aspirator. The plates were snap-
frozen and stored at -80 °C until further use. 
 
 
3.2.2 MALDI MS WHOLE CELL MEASUREMENTS 
 
3.2.2.1 SAMPLE PREPARATION 
 
In general, samples were prepared on a 384-well ground steel MALDI target plate (MTP). Prior 
to a new preparation, the MTP was placed into a beaker filled with MTP-cleaning solution and 
exposed to an ultrasonic bath for 15 mins.  
Cell aliquots were resuspended at 5,000 cells/µl in 50 % acetonitrile (v/v) in H2O which was 
supplemented with 5 µM malonyl-13C3 CoA for the FASN assay. 1 µl of the suspension was 
applied on the ground steel target in eight technical replicates. Samples from the same batch 
that were prepared on different days to evaluate intra-assay reproducibility are also referred to 
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as technical replicates with an indication of the time between the preparations. Cells that 
originate from different passage numbers are referred to as biological replicates. 
 
MTP-cleaning solution 
50 % Methanol 
45 % H2O 
5 %  Acetic acid 
 
3.2.2.2 AUTOMATED SAMPLE PREPARATION FOR THE FASN ASSAY 
 
The CyBio FeliX pipetting platform was used for automated sample preparation. Frozen 96-
well plates containing harvested cell pellets were placed on the instrument’s thermal mixer, 
BioShake, and warmed to room temperature. Cell pellets were resuspended in 40 µl 50 % 
acetonitrile (K562 cells) or pure H2O (A549 cells) supplemented with 5 µM malonyl-13C3 CoA 
using the CyBio 96-well 60 µl tip tray. The plate was shaken for 3 s at 2,000 rpm using the 
BioShake. The suspension was aspirated using the CyBio 96-well 60 µl tip tray. The instrument 
was paused for 5 s upon sample aspiration to saturate the gas phase above the liquids phase 
in the pipetting tip. 1 µl (K562 cells) or 2 µl (A549 cells) of the suspension were applied in 4-
fold technical replicates to a 384-well ground steel MALDI target plate. 
 
3.2.2.3 MATRIX APPLICATION 
 
Upon analyte application, the MALDI target was coated with matrix using a Sun Collect 
Sprayer. To avoid clogging of the sprayer with matrix crystals, each matrix preparation was 
exposed to an ultrasonic bath for 5 min. Additionally, the sprayer was thoroughly rinsed with 
50 % acetonitrile (v/v) in H2O before and after use. As a rule of thumb, 3 ml of matrix 
preparation are sufficient to coat a whole MTP with matrix. Matrix preparations and the matrix 
spray protocol are listed in the table below. The SunCollect sprayer was used throughout the 
whole thesis. A HTX sprayer was only used in combination with automated assays. The use 
of the HTX sprayer was implemented for the automated FASN assay, since it proved as a 
reliable and fast tool to spray-coat whole MALDI target plates. 
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Matrix preparation for standard fingerprinting and the tyrosine-kinase inhibitor 
assay 
20 mg/ml DHB 
50 % Acetonitrile 
50 % H2O 
0.5 %  Trifluoroacetic acid 
 
Matrix preparation for the FASN assay 
20 mg/ml DHB 
50 % Acetonitrile 
50 % H2O 
2.5 %  Trifluoroacetic acid 
 
Matrix spray protocol SunCollect sprayer 
Spray-head velocity 900 mm/min 
Spray-head height 2.8 cm 
Distance between 
sprayed lines 2 mm 
Matrix flow rate 30 µl/min 
Sprayed layers 10 
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Matrix spray protocol HTX sprayer 
Spray-head velocity 1000 mm/min 
Spray-head height 4 cm 
Distance between 
sprayed lines 2 mm 
Matrix flow rate 60 µl/min 
Sprayed layers 4 
Spray nozzle temperature 50 °C 
 
3.2.2.4 MALDI-TOF MS DATA ACQUISITION 
 
Early method development was performed on an autoflex speed MALDI-TOF/TOF mass 
spectrometer. Later on an ultrafleXtreme MALDI-TOF/TOF MS was used for this purpose due 
to its enhanced mass resolution. Both instruments were equipped with a 2 kHz smartbeam II 
laser. Automated data acquisition in the m/z range from 200 – 2,000 on both instruments was 
controlled by the AutoXecute function of the flexControl 3.4 software. 4,000 laser shots were 
accumulated per measuring spot in random walk mode. The laser focus was set to large on 
the autoflex or medium on the ultrafleXtreme. Laser intensity was adjusted to obtain signal 
intensities in the range of 103 and 104 AU. The sampling rate was adjusted to 4 giga samples 
/ s on the autoflex and to 5 giga samples / s on the ultrafleXtreme. 
Calibration of the instruments was performed using an in-house prepared mixture of the 
peptide calibration standard II (Bruker Daltonics) and the low molecular mass compounds 
sorafenib ([M+H]+ - 465.0935), romidepsin ([M+H]+ - 541.2149), sunitinib ([M+H]+ - 399.219), 
and olanzapine ([M+H]+ - 313.1481). 
Data acquisition for the FASN assay was performed on the rapifleX MALDI-TOF mass 
spectrometer. The instrument was equipped with a 10 kHz smartbeam 3D laser. Automated 
data acquisition was controlled by the AutoXecute function of the flexControl 4.0 software. 
Spectra were acquired in the m/z range from 500 – 1,000. 4,000 laser shots were accumulated 
per measuring spot in random walk mode. The laser focus was adjusted to “MS thin layer”. 
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Calibration of the rapifleX was performed internally using the lysophosphatidylcholine 
LPC(18:1) ([M+H]+ - 522.355), the phosphatidylcholine, PC(34:1) ([M+H]+ - 760.585 and 
[M+K]+ - 798.541) and malonyl-13C3-CoA ([M+H]+ - 857.126). 
 
3.2.2.5 MALDI-FTICR INSTRUMENT SETTINGS 
 
For structural elucidation of concentration-response marker molecules, sample spots exposing 
highest feature-of-interest intensity, were remeasured using an ultra-high resolution solariX 7T 
XR FTICR. The mass spectrometer was controlled by ftmsControl 2.1.0 software. In the first 
step, a full spectrum was acquired in the low molecular mass range (m/z 150 to 5,000) using 
a 4 M AMP transient. Laser intensity and shot per spot number were adjusted to obtain signal 
intensities between 108 and 109 AU. These settings enabled a typical resolving power of 
800,000 at m/z 400. Calibration was again performed externally using the calibration mixture 
described above. In addition, an abundant phosphatidyl choline at m/z 760.5851 
((PC(34:1)+H+) was used for internal, single point on-line calibration with a mass tolerance of 
6 ppm.  
The accurate mass of the marker molecule was determined from the full scan spectrum. For 
structural elucidation the marker molecule was fragmented. The instrument was set to tune 
mode to continuously acquire spectra. Quadrupole isolation was checked in the “Source 
MS/MS” tab. The isolation window was set to 1 m/z. RF frequency was set to 5. Collision cell 
RF amplitude was 2,000 V. The voltage for collision induced fragmentation was adjusted so 
that the intensity of the parent mass decreased to half of its initial intensity. 
 
Additional instrument settings solariX 
Ion transfer  
Voltage Funnel 1 150 V 
Voltage Skimmer 1 15 V 
Funnel RFamplitude 150 Vpp 
Octopole RF amplitude 350 Vpp 
RF frequency 5 MHz 
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Transfer optics 
Time off light 1.2 ms 
ICR Hexapole rod frequency 4 MHz 
Excitation mode Sweep mode 
Sweep step time 15 µs 
Ramped power exitation Continous (14-28 %) 
ICR Paracell 
Exit lens voltage -20 V 
Entrance voltage -10 
Front and back plate voltages 1.5 V 
Side-kick offset -1.5 V 
 
3.2.3 DATA ANALYSIS AND -VISUALIZATION USING COMMERCIAL SOFTWARE 
 
Gelview illustrations of MALDI-TOF spectra were generated using ClinProTools 3.0 software. 
MALDI-FTICR spectra were visualized using DataAnalysis 4.4 software. Sum formulae were 
calculated from MALDI-FTICR measurements using the SmartFormula function of 
DataAnalysis. 
 
3.2.4 DATA PROCESSING PIPELINE FOR MALDI-TOF DATA WRITTEN IN R 
 
MALDI-TOF data acquired on the autoflex, ultrafleXtreme or rapifleX were exported as text-
files using a flexAnalysis batch process. Data processing, analysis and visualization was 
performed in R programming language using RStudio [115]. 
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3.2.4.1 DATA PREPROCESSING  
 
Data were imported as text-files into R using the MALDIquantForeign package8. Preprocessing 
was performed using functions of the MALDIquant package [116]. The data processing 
workflow was adapted from Erich et al. [47] with the help of Denis Abu Sammour. The adapted 
workflow included TIC normalization of the spectra, “Tophat“ baseline subtraction, spectra 
alignment (tolerance = 0.002), peak picking of all signals with S/N > 5 (method = 
"SuperSmoother", halfWindowSize = 20, SNR > 5), peak binning (tolerance = 0.002) and 
calculation of a matrix containing all features (features matrix). The data preprocessing pipeline 
was implemented with the help of Denis Abu-Sammour. 
 
3.2.4.2 MULTIVARIATE DATA ANALYSIS USING PCA 
 
During the course of this thesis, principle component analysis (PCA) was employed to reduce 
spectral complexity and to obtain a simplified view on spectral similarities. Additionally, PCA 
scores were used as the basis for the calculation of Joverlap scores described below. For the 
work of this thesis, PCA was calculated based on the features matrix using the prcomp function 
of the R statistics package. 
 
3.2.4.3 MSEMOD-BASED METHOD SCORING  
 
The MSEmod –score is a modification of the previously published matrix suppression effect by 
lipids MSElip [49]. For MSEmod calculation all ions that were observed (S/N > 5) in the pure 
matrix spectrum were matched with the analyte spectrum (mass tolerance: 0.1 Da). The sum 
of ions in the analyte spectrum that did not occur in the matrix spectrum was divided by the 
sum of all ions observed in the analyte spectrum: 
𝑀𝑆𝐸𝑚𝑜𝑑 =  
∑ 𝑛𝑜𝑛 𝑚𝑎𝑡𝑟𝑖𝑥 𝑖𝑜𝑛𝑠
∑ 𝑎𝑙𝑙 𝑖𝑜𝑛𝑠
 
  
                                               
8 Gibb S (2015) MALDIquantForeign: Import/Export Routines for MALDIquant. 
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3.2.4.4 JOVERLAP-BASED METHOD SCORING 
 
The interclass overlap, Joverlap, is a score that compares different sets of experiments in the 
same PCA space and was determined as published by Erich et al. [47]. The score is described 
by the quotient of within-class scattering (WS) and between-classes scattering (BS): 
 
𝐽𝑜𝑣𝑒𝑟𝑙𝑎𝑝 =  
|𝑊𝑆|
|𝐵𝑆|
  
PCA was calculated based on the features matrix using the R statistics package. The 
DiscriMiner package9 was used to calculate WS and BS based on the coordinates of the 
datapoints in PCA space. The rgl package [117] was used for 3D-plotting of the PCA, as well 
as drawing of ellipsoids around each group and drawing distance lines between groups. 
 
3.2.4.5 EXTRACTION OF DRUG SENSITIVE M/Z FEATURES 
 
Drug sensitive m/z features were extracted using a two-step filtration strategy consisting of the 
exclusion of non-significant features in the first step and, in the second step, evaluation of how 
well the remaining features fit to a concentration response curve. Theresia Salonikios, a former 
PhD candidate in our laboratory, worked on MATLAB scripts for the extraction of protein 
response markers [118]. The idea to extract marker molecules by their fit to a concentration 
response curve originated from her work. Protein fingerprints and data analysis is based on 
broad linear mode peaks, whereas metabolites are measured in reflector mode. The feature 
extraction pipeline for metabolites was implemented in R programming language in 
collaboration with Timon Ulrich, a student of information technology. 
In the first step low variance features were excluded to omit non-significant masses that, by 
chance, might fit well to the concentration-response curve shape. Feature-wise variances 
across all datasets were calculated. The mean of all variances was used as a threshold to 
select masses of interest. Since the variance of most features was close to zero, the variances-
histogram was clearly right-skewed (Fig. 3.2.1). 
 
                                               
9 Sanchez G (2013) DiscriMiner: Tools of the Trade for Discriminant Analysis. 
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Figure 3.2.1: Variances-histogram of a 
concentration-response study. K562 cells 
were treated with 12 different concentrations of 
imatinib for 48 h. Samples were analyzed by 
MALDI MS whole cell fingerprinting. Feature 
wise variances across all 12 concentrations 
were calculated and illustrated as variances-
histogram. The red dashed line indicates the 
mean overall variance. All features falling to 
the right of this right-skewed histogram were of 
interest. 
 
 
In the second step all significant masses were fitted to concentration response curves using 
the nls function from R’s statistics package. Features exposing a descending concentration 
response were fitted to the equation: 
𝑓(𝑥) = 𝑡𝑜𝑝 +
𝑏𝑜𝑡𝑡𝑜𝑚 − 𝑡𝑜𝑝
1 + 10(𝐿𝑜𝑔𝐼𝐶50−𝑥) ∙ 𝐻𝑖𝑙𝑙𝑆𝑙𝑜𝑝𝑒
 
where f(x) is the signal intensity, x is the decadal logarithm of the drug concentration, top is 
the f(x) value at the top plateau, bottom is the f(x) value at the bottom plateau.  
For ascending concentration responses, the effect of hormesis needed to be taken into 
consideration. Mattson (2008) defined hormesis of cells as a stress response phenomenon 
charactericed by a low concentration induction and a high concentration inhibition [119]. To 
account for the occurrence of these biphasic responses, ascending concentration responses 
were only fitted up to the highest intensity value. Putative “toxic” concentrations following this 
global maximum were excluded. The remaining data points were fitted to the equation: 
𝑓(𝑥) = 𝑏𝑜𝑡𝑡𝑜𝑚 +
𝑡𝑜𝑝 −  𝑏𝑜𝑡𝑡𝑜𝑚
1 + 10(𝐿𝑜𝑔𝐼𝐶50−𝑥) ∙ 𝐻𝑖𝑙𝑙𝑆𝑙𝑜𝑝𝑒
 
R2 value was used to rate how well a concentration response curve explains the variation of 
the data. Features with R2 values below 0.9 were excluded. The remaining features were 
stored in lists. Concentration response curve fits were plotted using the ggplot2 package10.  
                                               
10 Wickham H (2009) ggplot2. Springer New York, New York, NY 
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4 RESULTS 
 
The results of this thesis are presented in three parts: 
 
- The first section presents the development of a broadly applicable IC-MALDI MS 
fingerprinting workflow. The section has a strong focus on method development which includes 
testing of parameters for sample preparation as well as various instrument settings. Moreover, 
the implementation of scores is presented to evaluate method performance by design of 
experiment principles. 
 
- The second section presents the application of the workflow, introduced in the first section, 
as a phenotypic assay to monitor BCR-Abl tyrosine kinase inhibition. The section also 
describes the development of an R software tool that enables automated data processing and 
extraction of concentration response markers. The identification of concentration response 
markers by MALDI-FTICR MS is demonstrated as well as how these markers can be used to 
compare drug potencies. 
 
- The third section presents the development of a mechanistic cell-based assay monitor 
inhibition of the fatty acid synthase. This section describes the discovery of CDP-choline as a 
marker for lipid synthesis inhibition as well as methods development of a standardized malonyl-
CoA-based assay readout. Moreover, the section describes the automation and parallelization 
of several liquid handling steps of the developed FASN assay to further direct MALDI MS cell 
assays towards routine use in compound profiling.  
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4.1 METHOD DEVELOPMENT METABOLITE-BASED IC-MALDI MS FINGERPRINTING 
 
Munteanu et al. developed a standardized IC-MALDI-TOF biotyping workflow based on protein 
fingerprints, which enables monitoring of drug action directly in whole cells [25, 29]. The aim 
was to develop an analogous workflow applicable for the detection of lipids and metabolites, 
which can be used to address medical, pharmaceutical and biotechnological issues. 
Metabolites detected in the low molecular m/z range interfere with the detection of small 
molecules used to facilitate the MALDI process like matrix and solvent additives. Therefore, 
the development of a metabolite-based workflow requires thorough optimization and 
evaluation. 
 
4.1.1 APPLICATION OF A SCORE-BASED METHOD DEVELOPMENT APPROACH 
 
When developing a MALDI-TOF fingerprinting method of whole cells, the identity of the 
detected molecules is not necessarily known. Guided by design of experiment principles, two 
score-based approaches were adapted from the literature to evaluate method performance. 
To compare different preparation protocols three cancer cell lines were cultured. These cell 
lines included one gastrointestinal stromal tumor cell line T1 (GIST) as well as the two leukemia 
cell lines, HL60 and K562. Data acquired using a well-performing preparation protocol are 
expected to expose striking, biological differences among the three cell lines and to therefore 
enable clear data separation in PCA space. Joverlap is a score to quantitatively compare 
separation efficiency as well as data scattering in PCA space between datasets (here: cell 
lines) [47]. Another score that enables to approximate the information content of a mass 
spectrum is the matrix suppression effect (MSE) by lipids [49]. A modification of this score, 
MSEmod, was used to compare the ratio of matrix signals to analyte signals among different 
preparation protocols. 
The lack of any commercially available software to calculate these scores required the in-
house development of a data processing pipeline. The Strimmer group laid an excellent 
foundation with the publication of the MALDIquant software package written in R [116].  
The package contained the most comprehensive tools for MALDI-TOF data preprocessing 
among the open source programming languages. Spectra acquired on an ultrafleXtreme 
MALDI-TOF MS were exported as text-files using a flexAnalysis batch process. Import of text-
files into R using the MALDIquant foreign package proofed as a reliable strategy. This strategy 
was especially preferred over the direct import of Bruker fid-files, which led to a loss of spectral 
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calibration information. Several preprocessing functions were successfully adapted from the 
MALDIquant package as described by Erich et al. [47] including spectra normalization to the 
total ion current, alignment, peak picking and binning. Processing of spectra in R enabled 
sensitive and robust detection of signals (Fig. 4.1.1 A,B). The detected signals are stored in a 
feature matrix, which is used for further investigations, such as score-based method 
development.  
 
 
Figure 4.1.1: Data processing pipeline. Spectra acquired on an ultrafleXtreme were 
exported as text-files and loaded into R-programming environment. A,B) Zoom in of two mass 
spectra of K562 cells treated with different Imatinib concentrations before (A) and after (B) 
preprocessing. Detected signals are illustrated as green dots. 
 
Starting method development with 5,000 cells/spot, a cell number compatible with the 
previously published protein-based IC-MALDI MS workflow, the matrices 6-aza-2-thiothymine 
(ATT) and 2,5-dihydroxybenzoic acid (DHB) were compared (Fig. 4.1.2). Both matrices were 
previously reported for the analysis of multiple lipid classes [38, 120]. To avoid formation of 
large matrix crystals, MALDI targets were spray-coated with a SunCollect device utilizing a 
rather dry spray protocol. A smaller Joverlap value suggested a preference for DHB (Joverlap = 
0.14) over ATT (Joverlap = 0.39) in this experimental setting. Reevaluation of both biological 
replicates in separate PCA spaces confirmed the lower Joverlap score for DHB (Joverlap = 0.14 ± 
0.05) compared to ATT (Joverlap = 0.32 ± 0.01). 
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Figure 4.1.2: Using DHB as matrix leads to better separation in PCA space compared to 
ATT matrix. Cell pellets of three different cell lines (GIST, K562 and HL60) were resuspended 
at 5,000 cells/µl in acetonitrile/H2O. One microliter of the suspension was applied on a MALDI 
target plate, which was spray-coated with either DHB (A; 20 mg/ml in acetonitrile/H2O/TFA 
(60/40/0.5)) or ATT (B; 10 mg/ml in the same solvent). Samples were measured using an 
autoflex Speed MS. PCAs and variances were calculated in R. Biological replicates are colored 
in different shades of the same color (m/z 200-2000, S/N > 5, n = 2 biological replicates, each 
with ≥ 8 technical replicates measured on the same day). 
 
None of the SunCollect sprayer-compatible solvent mixtures tested for resuspension of cell 
pellets increased the number of features detected with S/N >10 (Fig. 4.1.3). Also the 
implementation of an additional hexane extraction step did not improve separation efficiency 
for three different cell lines, as assessed by Joverlap value (Fig. 4.1.4). Results obtained from 
Joverlap analysis were supported by MSEmod analysis (Fig. 4.1.5). Combination of the solvent 
50 % acetonitrile in water and the matrix DHB led to an improved matrix suppression. 
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Figure 4.1.3: Tested solvents for 
sample resuspension. The 
number of features (S/N > 10, m/z 
500-2000) does not significantly 
depend on the solvent mixture used 
for resuspension of cells. Number 
of features is plotted against the 
solvent used for sample 
resuspension and matrix 
application (5,000 cells/spot, mean 
± standard deviation for n = 3 
technical replicates prepared in 8-
fold replicates on different days). 
 
 
Figure 4.1.4: Direct sample resuspension in acetonitrile/H2O is more advisable than 
hexane extraction. (A) Cell pellets of three different cell lines (GIST, HL60 and K562) were 
suspended at 5,000 cells/µl in acetonitrile/H2O (1/1). 1 µl of the suspension was applied on the 
MTP (5,000 cells/spot). (B) Hexane was added (1/1) to the acetonitrile/H2O suspension. 
Samples were vortexed and centrifuged for 30 s at 14,000 rpm for phase separation. 1 µl of 
the hexane extract was applied on the MTP. Cells were spray-coated with DHB matrix (20 
mg/ml in acetonitrile/H2O/TFA (60/40/0.5)). Samples were measured using an autoflex MS. 
The illustrated PCAs and variances were calculated in R. Biological replicates were colored in 
different shade of the same color (m/z 200-2000, S/N > 5, n = 2 biological replicates with ≥ 8 
technical replicates measured on the same day, the figure was adapted with slight 
modifications from Weigt et al., 2018 [121]). 
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Figure 4.1.5: Validation of Joverlap scores. K562 cell pellets were resuspended at 5,000 
cells/µl in acetonitrile/H2O (1/1). 1 µl of the suspension was applied on the MTP (5,000 
cells/spot). Hexane was added (1/1) to the acetonitrile/H2O suspension. Samples were 
vortexed for 30 s. For phase separation, samples were centrifuged for 30 s at 14,000 rpm. 1 
µl of the hexane extract was applied on the MTP. Cells were spray-coated with DHB matrix: 
20 mg/ml in acetonitrile/H2O/TFA (60/40/0.5) or ATT matrix: 10 mg/ml in the same solvent. 
Samples were measured using an autoflex MS. (A) Spectra are illustrated as gel view 
generated by ClinProTools software. Pure matrix spectra are illustrated as control. (B) The 
MSEmod score was plotted for the different solvent and matrix combinations (m/z 200-2000, 
S/N > 5, n = 2 biological replicates with ≥ 8 technical replicates measured on the same day). 
 
The initial, rather “dry” matrix application protocol (15 µl/min flow of matrix solution) was 
investigated in more detail. Joverlap scores suggested that slightly better separation of data sets 
in PCA space was obtained when a “wet” (30 µl/min flow of matrix solution) matrix application 
protocol was used instead (Fig. 4.1.6).  
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Figure 4.1.6: Preference for a wet matrix application protocol. Cell pellets of three different 
cell lines (GIST, HL60 and K562) were suspended at 5,000 cells/µl in acetonitrile/H2O (1/1). 1 
µl of the suspension was applied on the target plate (5,000 cells/spot). Matrix (20 mg/ml DHB 
in 50% acetonitrile, 0.2% TFA) was applied following different spray-protocols using the 
SunCollect sprayer. The spray head was either moved fast (1250 mm/min) or slow (900 
mm/min). Matrix flow rate was either adjusted to “dry” (15 µl/min) or to “wet” (30 µl/min). 
Samples were measured on an ultraflex. The illustrated PCAs of samples prepared following 
a fast-dry (A), a fast-wet (B), and a slow-wet (C) spray protocol were calculated in R (m/z: 200-
2000, n ≥ 8 technical replicates). 
 
Munteanu et al. as well as Smolira et al. described in previous studies the importance of the 
analyte-to-matrix ratio for an optimized signal readout and to reproducibly acquire mass 
spectra [25, 122]. Therefore, it was aimed to fine-tune the amount of cells per measuring spot 
as the final step of workflow development. A cell dilution series was performed and the ideal 
amount of analyte again was determined by the matrix suppression effect, MSEmod score. A 
“by eye” analysis of the gel view revealed increased suppression of matrix ions with increased 
cell numbers applied per measuring spot (Fig. 4.1.7 A). The majority of remaining matrix 
signals was observed below m/z 500. A plot of the cell number against the MSEmod revealed 
that the MSEmod did not significantly increase with cell numbers greater than 5,000 cells/spot. 
Since the amount of detected analyte molecules seemed to plateau at 5,000 cells/spot, this 
amount was chosen for the final workflow (Fig. 4.1.7 B). 
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Figure 4.1.7: Effective suppression of matrix ions at 5,000 cells per measuring spot. A 
dilution series of K562 cells was prepared in acetonitrile/H2O (1/1) and applied to an MTP. The 
plate was spray coated with 20 mg/ml DHB matrix resuspended in acetonitrile/H2O/TFA 
(50/50/0.5) and measured by an ultrafleXtreme. 4,000 shots per measuring spot were acquired 
in reflector positive ion mode. (A) Spectra were illustrated as a gel view using ClinProTools 
software. (B) The cell number per measuring spot was plotted against the MSEmod score 
calculated in R (mean ± standard deviation for n = 3 technical replicates prepared on different 
days). 
 
The use of a matrix sprayer resulted in homogenously distributed matrix crystals (Fig. 4.1.8 
A), which was critical for the automated acquisition of mass spectra. However, matrix 
application via spray coating requires the use of an additional instrument which increases 
sample preparation time as well as the cost of equipment. Therefore, several substituting 
methods to enable a homogenous DHB matrix application were tested. Even though none of 
the evaluated methods led to a successful replacement of the matrix spray application, the 
tested approaches are presented as incentives for future developments. Resuspension of cell 
pellets in aqueous DHB matrix and direct application to a MALDI target plate is not advisable 
due to the formation of large matrix crystals at the outer ring of the sample spot (Fig. 4.1.8 B). 
Addition of the humectants glycerol and DMSO was tested to delay the crystallization of DHB 
matrix. Upon desiccation of the samples at less than 1 millibar for 1 h homogenously distributed 
matrix crystals were observed (Fig. 4.1.8 C,D). Due to the available vacuum apparatus the 
drying was tedious and often incomplete (Fig. 4.1.8 E). Munteanu et al. described the use of 
sinapinic acid precoated MALDI target, to provide anchor crystals for the sample and matrix 
mixture [25]. In contrast to sinapinic acid, DHB precoated on MALDI target plates (Fig. 4.1.8 
F) is easily dissolved upon application of aqueous or polar solvents (Fig. 4.1.8 G). Application 
of non-polar solvents on the polar surface led to widely dispersed sample spots. Nitrocellulose 
has been described to form homogenous thin layers that are resistant to most solvents, 
suppress matrix ions and do not generate endogenous signals [123]. The formation of a 
nitrocellulose thin layer that enables homogenous sample application was observed (Fig. 4.1.8 
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H). Unfortunately, a standardized reproduction of the result was not achieved. The use of 
benzoic acid was tested for the interference with DHB crystallization. Addition of benzoic acid 
resulted in a crystalline layer on the sample spot (Fig. 4.1.8 I). The addition of benzoic acid 
was not pursued further, since benzoic acid is not stable in ultra-high vacuum ion sources. 
Figure 4.1.8: Evaluation of DHB matrix application protocols. MALDI ultrafleXtreme or 
autoflex camera images of sample spots prepared according to the following protocols: A) 
K562 cells were resuspended at 5,000 cells/µl in acetonitrile/H2O. One microliter of the 
suspension was applied on a MALDI target plate, which was spray-coated with DHB matrix 
(20 mg/ml in acetonitrile/H2O/TFA (50/50/0.5)). B) K562 cells were resuspended at 5,000 
cells/µl in DHB matrix (20 mg/ml in acetonitrile/H2O/TFA (50/50/0.5)). One microliter of the 
suspension was applied on a MALDI target plate. C) K562 cells were resuspended at 5,000 
cells/µl in DHB matrix (10 mg/ml in H2O) supplemented with 0.1 % TFA and 8 % 
glycerol/methanol (2/1). Samples were dried in desiccator for 60 min. One microliter of the 
suspension was applied on a MALDI target plate. D, E) K562 cells were resuspended at 5,000 
cells/µl in 10 mg/ml DHB matrix (10 mg/ml in H2O) supplemented with 0.1 % TFA and 2.5 % 
DMSO. Samples were dried in a desiccator for 60 min. One microliter of the suspension was 
applied on a MALDI target plate. D) Completely dried sample. E) Incompletely dried sample. 
F,G) DHB matrix (60 mg/ml in ethanol) was equally spread on a MALDI target plate (F). One 
microliter H2O was applied onto the DHB thin-layer (G). H) Nitrocellulose-solution (20 mg/ml 
in acetone/propan-2-ol (1/1)) was equally spread on a MALDI target plate. K562 cells were 
resuspended at 5,000 cells/µl in DHB matrix (10 mg/ml in acetonitrile/H2O/TFA (50/50/0.1)) 
and one microliter of the suspension was applied on the nitrocellulose thin layer. I) K562 cells 
were resuspended at 2,500 cells/µl in DHB matrix (20 mg/ml in acetonitrile/H2O/TFA 
(60/40/0.2)) supplemented with 20 mg/ml benzoic acid.  
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4.1.2 EVALUATION OF THE DEVELOPED MALDI MS SMALL MOLECULE FINGERPRINTING APPROACH 
 
The final workflow was tested for its ability to separate three cancer cell lines in replicate 
measurements performed weeks apart from each other (Fig. 4.1.9 A). The workflow enabled 
separation in PCA space, indicating that the detected biological variances outweigh variances 
caused by technical divergences. It is also noteworthy that these cell lines were all cultivated 
under similar conditions in culture medium mainly supplemented with FCS. This has been 
described to cause metabolic adaptations along with the suppression of physiologic pathways 
[124]. Application of the developed workflow for studies on primary cells likely harbors even 
more prominent biologic characteristics.  
Correlation analysis of K562 cell pellets prepared on different days was chosen as a second 
approach to assess technical repeatability (Fig. 4.1.9 B-D). The analysis was focused on 
intensities in the lower 95th percentile to avoid a distortion of the correlation by prominent 
signals. A correlation coefficient, R2, of 0.77 ± 0.07 suggests adequate repeatability of the 
workflow.  
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Figure 4.1.9: Evaluation of IC-MALDI MS lipid/metabolite fingerprints repeatability. Cell 
pellets of three different cell lines (GIST, HL60 and K562) were resuspended at 5,000 cells/µl 
in acetonitrile/H2O (1/1). 1 µl of the suspension was applied on the MTP (5,000 cells/spot). 
Cells were spray-coated with DHB matrix (20 mg/ml in acetonitrile/H2O/TFA (60/40/0.5)). 
Samples were prepared separately for measurement on an ultrafleXtreme. (A) PCA and 
variances were calculated in R (S/N > 5, m/z 200-2000, n = 3 biological replicates with 
respectively ≥ 8 technical replicates measured on different months). (B-D) Mean intensities of 
all peaks (S/N > 5, m/z 200-2000) corresponding to K562 cells independently prepared and 
measured on different days. Peaks with intensities above the 95th percentile were excluded. 
 
A prerequisite for the detection of metabolites is the co-crystallization of matrix and analyte. 
Reproducible application of MALDI matrix therefore is of central importance for a standardized 
workflow. A proposed quality assurance measure is to weigh the sample mounted on a 
microscope slide prior to measurement before and after matrix coating [125]. Yet, this measure 
is not applicable to samples applied on a 230 g ground steel MALDI target, which is coated 
with ~20 mg of DHB matrix. The proposed more practical solution is a by eye evaluation of 
matrix crystal size and distribution (Fig. 4.1.10). Crystals forming in areas where no sample is 
applied, typically are shorter than 100 µm and not further apart than 20 µm. Matrix crystals are 
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more densely dispersed on spots containing sample due to co-crystallization of analyte and 
matrix. 
 
Figure 4.1.10: Monitoring of matrix application performance. K562 cells were 
resuspended at 5,000 cells/µl in acetonitrile/H2O (1/1). 1 µl of the suspension was applied on 
the MALDI target plate (5,000 cells/spot). The target plate was coated with DHB matrix (20 
mg/ml in acetonitrile/H2O/TFA (60/40/0.5)). Optical images of blank spots (A,C) or sample 
coated spots (B,D) were acquired at different magnifications using a Keyence digital 
microscope. 
 
To investigate if the final workflow could also be used for analysis and classification of tissue 
homogenates, five different tissue homogenates (brain, liver, pancreas, spleen, skeletal 
muscle) were measured, which were independently prepared for measurement on three 
different days (Fig. 4.1.11). All homogenates were separated in PCA space suggesting wider 
applicability of the developed method.  
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Figure 4.1.11: Small molecule fingerprinting workflow can be applied to fingerprinting 
analysis of cell-free tissue extracts with high technical reproducibility. Five snap-frozen 
bovine tissues were cut into small cubes (1 mm3). Cubes were transferred to 15 ml conical 
tubes and resuspended at 50 mg/ml in H2O containing complete protease inhibitor cocktail. 
The tissue cubes were homogenized for 40 sec using a polytron manual dispenser. Snap-
frozen homogenates were thawed on three different days and further processed for MALDI-
TOF MS measurement. Homogenates were diluted in acetonitrile/H2O (1/1) to a final 
concentration of 10 µg wet weight tissue per µl. 1 µl of the solution was applied to the target 
plate. Dried sample spots were spray-coated with DHB matrix (20 mg/ml in acetonitrile/H2O 
(1/1)). The target was measured using an ultrafleXtreme in reflector positive ion mode. Feature 
extraction and PCA calculation was performed in R. PCA of all five homogenates demonstrates 
robust discrimination of small molecular fingerprints. Technical replicates measured on 
different days are colored in different shades of the same color (n = 3 technical replicates 
prepared in 8-fold replicates on different days). 
 
Workflow optimization aimed at increasing the information of cell fingerprints (by increasing 
MSEmod) without being aware of the underlying metabolites and lipids. This was mainly due to 
the low mass resolving power of the ultrafleXtreme MALDI-TOF MS that was available for 
method development. A list of putative identities of detected metabolites and lipids that was 
supported by MALDI-FTICR remeasurements and database search is provided in table 4.1.1. 
It is worth mentioning that the list is not exhaustive, since only a minor fraction of the detected 
signals was subjected to data-base search.  
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Table 4.1.1: Candidate cellular 
metabolites and lipids detected by the 
developed MALDI-TOF MS 
fingerprinting workflow. m/z values of 
singly charged molecules or their detected 
proton adducts are presented. The identity 
hypothesis was supported by MALDI-
FTICR accurate mass remeasurements. 
LPE – lysophatidylethanoylamine 
CDP – cytidine diphosphate 
LPC – lysophatidylcholine 
NAD(P) – nicotinamide adenine 
dinucleotide (phosphate) 
SM – Sphingomyeline 
PC – phosphatidyl choline 
Lipids marked with asterisks were only 
observed in brain homogenates. The list is 
not exclusive and does not include 
measurements of pure or spiked standards. 
 
metabolite/lipid m/z 
LPE(18:1)+H+ 480.3085 
CDP-choline+H+ 489.1146 
LPC(16_0)+H+ 496.3398 
LPC(18_1)+H+ 522.3554 
Heme B+ 616.1924 
NAD+ 664.1164 
SM(36_1)+H+ * 731.6061 
PC(32_0)+H+ 734.5694 
NADP+ 774.0827 
PC(34_1)+H+ 760.5851 
PC(36_4)+H+ 782.5694 
PC(36_1)+H+ 788.6164 
PC(38_4)+H+ 810.6007 
SM(42_2)+H+ * 813.6844 
Malonyl-CoA+H+ 854.1229 
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4.2 DEVELOPMENT OF A PHENOTYPIC ASSAY FOR BCR-ABL TYROSINE KINASE INHIBITORS  
 
BCR-Abl is a well characterized, clinical relevant drug target [100]. Breitkopf et al. showed that 
tyrosine kinase inhibitor treatment affects the metabolome and lipidome of cultured cells [102]. 
Therefore, tyrosine kinase inhibition of the BCR-Abl positive K562 cell line was chosen as an 
example to integrate the developed metabolite-based IC-MALDI MS workflow into a cell-based 
assay for drug discovery. The developed workflow aims at supporting drug discovery in two 
conceivable ways (Fig. 4.2.1).  
The first application deals with the identification of candidate pharmacodynamics biomarkers, 
i.e. of drug-sensitive m/z features. Cultivated cell lines are treated with various concentrations 
of well-characterized inhibitors. Upon incubation, the cells are harvested and applied on a 
ground steel MALDI MS target plate. The plate is spray-coated with DHB matrix and 
automatically analyzed by an ultrafleXtreme MALDI-TOF MS. The acquired data are imported 
into R. Drug-sensitive m/z features are extracted in a two-step filtration strategy (chapter 
4.2.1.). In short, first features are filtered by their variance spanning all datasets. Then features 
are filtered by their fit to a concentration-response curve. Extracted features exposing the best 
curve-fit, candidates for so called concentration-response or pharmacodynamic markers, are 
structurally elucidated by MALDI-FTICR MS/MS. 
In the second scenario, a previously identified concentration-response marker is employed for 
the discovery of novel inhibitors. Cell cultures are treated with compounds of unknown activity. 
The activity of compounds is evaluated based on the response of a defined marker molecule. 
This second, throughput-oriented workflow relies only on the use of the fast MALDI-TOF mass 
spectrometer. 
The first workflow was developed by treating K562 cells with the well-characterized tyrosine 
kinase inhibitor imatinib. An initial single replicate experiment revealed that distinctness among 
treated and control cells increased with the inhibitor incubation time (Fig. 4.2.2 A). Most striking 
differences among treated and control group were observed after 72 h, which was confirmed 
by Joverlap analysis (Fig. 4.2.2 B). However, assessment of cellular viability by trypan blue 
staining gave evidence for widespread cell death at that time point. 48 h inhibitor incubation 
was chosen instead, because it enabled clear separation in PCA-space at >80 % viability of 
the control. 
The next sections focus on the development of an automated data processing pipeline, the 
identification of marker molecules by FTICR-MS/MS (workflow 1) and application of the 
concentration-response markers for potency evaluation of drugs (workflow 2). 
- 60 - 
 
 
Figure 4.2.1: Concentration-response marker workflows. Cell lines are cultured in 6- or 24-
well plates and treated with various concentrations of (1) well-characterized or (2) novel 
inhibitors. Upon inhibitor incubation, cells are harvested and snap-frozen. Cell pellets are 
resuspended in acetonitrile/H2O (1/1). 1 µl is applied on a 384-well MTP (5,000 cells/spot). The 
target is coated with DHB (20 mg/ml in acetonitrile/H2O/TFA (50/50/0.5)). Data are 
automatically acquired by an ultrafleXtreme MALDI-TOF mass spectrometer. Data are loaded 
into R programming language for preprocessing. (1) Drug sensitive m/z features are filtered 
by their variance and their fit to a concentration response curve. Extracted features are 
structurally elucidated by MALDI-FTICR MS/MS. (2) Compounds that induce a response of the 
marker molecule are identified as promising drug candidates (This image was adapted with 
some modifications from Weigt et al., 2018 [121]).  
- 61 - 
 
Figure 4.2.2: Increased incubation time favors separation of control and Imatinib treated 
cells in PCA space. K562 cells were treated with 1 µM imatinib in a time course. Imatinib 
treatment was stopped by cell harvest after 6, 24, 48 and 72 h. Samples were measured by 
an ultrafleXtreme in reflector positive ion mode. Feature extraction, PCA calculation (A) and 
Joverlap analysis (B) was performed in R. (n = 8 technical replicates measured on the same day). 
 
4.2.1 AUTOMATED EXTRACTION OF CONCENTRATION RESPONSE MARKERS 
 
A whole cell spectrum acquired by the developed MS fingerprinting workflow typically contains 
> 500 signals (S/N > 5, m/z 200-2000). This number of features and the lack of any 
commercially available software required the in-house development of a pipeline to 
automatically extract drug sensitive m/z values.  
The fundamental idea of the developed pipeline is that drug-sensitive m/z features show 
unique curve shapes in a concentration-response plot. For this reason, every relevant m/z 
feature was fitted to its specific concentration-response curve. Since hundreds of features were 
extracted during data preprocessing, several signals fitted a concentration-response curve-fit 
due to noise fluctuation. To exclude statistical noise, feature variances spanning all data sets 
were calculated. Plotting the feature variances against their frequency produced a right skewed 
histogram (Fig. 4.2.3 A). All features with a variance smaller than the total median variance 
were excluded from concentration-response fits. PCA supported the variance-based feature 
filtering approach (Fig. 4.2.3 B). Low variance features localized at the center of the loadings 
plot, whereas the interesting features represented the outliers of the loadings plot. 
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Figure 4.2.3: Variance-based feature filtering. A,B) Spectra acquired on an ultrafleXtreme 
were exported as text-files and loaded into R. Mass features exposing variances lower than 
the median variance of all features were excluded. These features fall to the left of the red 
dashed line in a variance histogram (A) and are typically located in the center of a loadings 
plot (B) while outliers (illustrated in red) are chosen for concentration response curve fits (This 
figure was adapted with some modifications from Weigt et al., 2018 [121]). 
 
Besides the necessity of a filtering step, additional valuable conclusions were drawn from the 
development of a data analysis pipeline based on the example of imatinib treated K562 cells. 
The initial data processing pipeline aimed at the discovery of features that exposed a good fit 
to either an ascending or a descending concentration-response curve. An m/z value was fitted 
to a decreasing concentration-response if its intensity (I) was greater at the control treated 
sample (ctr) compared to the sample treated with the highest inhibitor concentration (cmax) 
and vice versa: 
Descending curve fit: Ictr > Icmax 
Ascending curve fit: Ictr < Icmax 
This approach enabled to extract m/z 826.6 as a marker for a descending concentration-
response (Fig. 4.2.4 A). The descending concentration response model fitted best for the 
signal intensities of m/z 826.6, among several m/z values that showed an imatinib 
concentration-dependent decrease, rated by R² value. The extraction of features that increase 
upon imatinib treatment only revealed an R² > 0.9 for the compound imatinib (m/z 494.2) itself 
(Fig. 4.2.4 B) but no signals related to a treatment effect. This derived the hypothesis that 
eventual marker molecules are induced at low concentrations whereas no response is 
observed at high concentrations because of cell death. This kind of biphasic [126] or inverted 
U-shaped [127] concentration-response has been previously observed. The hypothesis was 
supported by a descending cellular viability of K562 cells, determined by MTT assay, at high 
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concentrations of imatinib treatment. The identification of biphasic concentration-response 
markers was based on a new criterion that the maximum feature intensity (Imax) was reached 
somewhere between the control group and the highest concentration, cmax. All feature 
intensities greater Imax were excluded and the remaining features were fitted to an ascending 
curve, which had to be defined by at least 5 data points. The approach enabled the extraction 
of m/z 616.2, which displayed a biphasic concentration response in three biological replicates 
(Fig. 4.2.4 C). 
 
Figure 4.2.4: Small molecular features extracted from K562 fingerprints enable 
monitoring of imatinib concentration response. K562 cells were treated with various 
concentrations of imatinib and measured by an ultrafleXtreme. A data processing pipeline 
developed in R enabled the extraction of features that exposed descending (A), ascending (B) 
and biphasic (C) concentration-responses (mean ± SD of n = 3 biological replicates with 8 
technical replicates each). D) Multivariate data analysis revealed groups of spectra of cells 
treated with similar concentrations of imatinib. Different imatinib concentrations are highlighted 
by a rainbow color scheme starting from the lowest concentration in red to highest 
concentration in violet (n = 8 technical replicates). 
 
Interestingly, multivariate data analysis revealed that groups of spectra form clusters in PCA 
space related to imatinib concentration (Fig. 4.2.4 D): the spectra can be divided into low (0 – 
0.1 µM), intermediate (0.3 – 3 µM) and high (10 – 30 µM) drug treated groups. This supports 
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the notion that biological effects, which in this case originate from the inhibitor treatment, 
outweigh technically attributed variances.   
 
4.2.2 MARKER IDENTIFICATION USING MALDI-FTICR 
 
The two extracted response marker m/z were subjected to molecular elucidation. As part of 
the response marker workflow, both features were remeasured using an ultra-high resolution 
7T solariX FTICR (Fig. 4.2.5). Sample spots that had displayed highest feature of interest 
signal intensities during earlier MALDI-TOF analysis were used for MALDI-FTICR 
remeasurements and revealed more precise m/z 616.1767 and m/z 826.5722 for the low-
resolution mass features m/z 616.2 and m/z 826.6, respectively.  
Fortunately, the MALDI-FTICR remeasurements did only reveal a single high-resolution m/z 
feature underlying each low-resolution response marker. Noteworthy, it is likely that one low-
resolution m/z feature harbors two or more molecular species, which would hamper its use as 
a response marker in fast MALDI-TOF analysis. An example from unrelated work are the 
phosphatidyl cholines (PC), PC(36:4) + H+ (m/z 782.5694) and PC(34:1) + Na+ (m/z  782.5670) 
which are distinguishable by MALDI-FTICR but not by MALDI-TOF MS.  
Interestingly, the increase of m/z 616.2 (Fig. 4.2.5 A) and the decrease of m/z 826.6 (Fig. 4.2.5 
B) upon 1 µM imatinib treatment was also observed in high-resolution measurements. This 
comparable sensitivity of low and high-resolution features to imatinib is another observation 
supporting the hypothesis that the detected high-resolution features correspond to the 
extracted low-resolution response markers. 
High-resolution m/z features were subjected to database search using the human metabolome 
database (www.hmdb.ca). Search results with a mass accuracy better than 3 ppm were 
included. The list of potential adduct forming ions included protons, sodium and potassium. 
Moreover, search results proposing lipids with uneven carbon numbers in the fatty acid chain 
were excluded. The only result fulfilling these criteria for the search of m/z 616.1767 was heme 
B (m/z 616.1767, Δm = 0.03 ppm). The search of m/z 826.5722 revealed the potassium adduct 
of PC(36:1) (m/z 826.5723, Δm = 0.1 ppm) as the most promising candidate. Distribution of 
lipid chain length as well as position and stereo isomers of double bonds, which are notoriously 
difficult to analyze by MALDI MS [128] were not differentiated.  
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Figure 4.2.5: Remeasurement of low-resolution, putative m/z features by ultra-high 
resolution solariX MALDI-FTICR MS. Spots containing mock-treated cells (control; red 
spectra) and cells treated with 1 µM imatinib (green spectra) were measured using both 
MALDI-TOF (A,B) and MALDI-FTICR MS (C-F). For the low-resolution feature m/z 616.2 (A), 
a more precise m/z 616.1767 was obtained using high resolution MS (C,E). The low resolution 
feature m/z 826.6 (B) corresponds to the high resolution m/z 826.5722 (D,F). 
 
The proposed molecular candidates underwent structural elucidation by MALDI-FTICR 
MS/MS. Fragmentation of the high resolution feature m/z 616.1767 confirmed the signal as 
heme B by revealing signals corresponding to the loss of the CH2COOH carboxylic acid side 
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chains (Fig. 4.2.6 A). High resolution MS/MS also confirmed m/z 826.5722 as the potassium 
adduct of PC(36:1) (Fig. 4.2.6 B). Signals corresponding to the loss of trimethylamine and the 
PC head group as well as a signal corresponding to a cyclophosphane ring (m/z 162.96) were 
detected. The fragments assignable to the PC were all detected as potassium adducts. 
 
 
Figure 4.2.6: Identification of candidate response markers using MALDI-FTICR MS/MS. 
Spots that show highest feature of interest intensity were remeasured using a MALDI solariX 
7T FTICR. Mass features were isolated using the instruments quadrupole and subjected to 
fragmentation. A) A spot containing 1 µM imatinib-treated cells exposed highest intensity of 
the feature m/z 616.1767. B) A spot containing DMSO-treated cells exposed highest intensity 
of the feature m/z 826.5722 (This figure was adapted with some modifications from Weigt et 
al., 2018 [121]).  
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4.2.3 USE OF CONCENTRATION-RESPONSE MARKERS TO COMPARE DRUG POTENCIES 
 
Heme B is the prosthetic group of heme proteins, which is produced in K562 cells during 
erythropoiesis. Erythropoiesis is a known indicator of redifferentiation of CML cells and thus a 
known indicator of successful action of Bcr-Abl inhibitors [129]. Heme B synthesis and 
degradation in K562 cells is tightly regulated due to the toxicity of free heme B [130]. PC(36:1) 
is a phospholipid molecule that is predominantly found in the plasma membrane. The decrease 
of PC(36:1) + K+ in imatinib-treated K562 cells may be related to cell viability for two reasons: 
On the one hand apoptosis has been described to induce the expression of lipid degrading 
enzymes [131]. Additionally, apoptotic events are associated with a dysfunction of the Na/K-
ATPase, which maintains membrane resting potential and indirectly cellular osmosis [132]. A 
loss of intracellular potassium might cause a pronounced decrease in potassium adduct 
formation during the MALDI process. 
Since the whole cell fingerprint enables a simultaneous readout of both erythropoiesis and a 
process that is hypothesized to be apoptosis, it was important to test if the response of these 
molecules was specific for imatinib treatment or whether their readout was of a broader 
applicability. 
A variety of inhibitors was chosen including the second line and second generation BCR-Abl 
specific inhibitors nilotinib and dasatinib as well as vandetanib that was designed as an EGFR 
and VEGFR inhibitor but also targets BCR-Abl [133, 134]. The drug sunitinib was chosen as a 
drug that inhibits multiple receptor tyrosine kinases but not BCR-Abl [135]. The anti-malaria 
drug chloroquine was chosen as a non-tyrosine kinase inhibitor drug.  
In concentration-dependence experiments both heme B and PC(36:1) + K+ responded to all 
inhibitors that have been described to target BCR-Abl (Fig. 4.2.7). Among the tested inhibitors, 
the strongest response was observed for dasatinib, followed by nilotinib, imatinib and 
vandetanib. No heme B induction was observed for sunitinib or chloroquine. The marker 
molecules proofed as valuable measures to perform drug potency evaluation in K562 cells and 
appear selective for BCR-Abl inhibitors. 
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Figure 4.2.7: Drug potency evaluation using Heme B and PC(36:1) + K+. K562 cells were 
treated with various concentrations of the indicated inhibitors and analyzed by an 
ultrafleXtreme MS. The applied amounts of inhibitor were plotted against the signal intensities 
of heme B (m/z 616.2, A) and PC(36:1) + K+ (m/z 826.6, B) (mean ± SD of n = 3 biological 
replicates with 8 technical replicates each, this figure was adapted with some modifications 
from Weigt et al., 2018 [121]). 
 
Since the decrease of PC(36:1)+K+ was assumed to be related to apoptosis the use of m/z 
826.6 as a viability marker was assessed. The descending curve shapes of m/z 826.2 were 
used to extract pIC50 values and compare these to viability data measured by MTT assay 
(Fig. 4.2.8). Standard deviations of pIC50 values derived from three biological replicates by 
MS experiments were comparable to those obtained by MTT assay (≤ 0.2) suggesting good 
experimental repeatability. Moreover, the pIC50 values obtained by MS and MTT were 
comparable (ΔpIC50 ≤ 0.4), suggesting usability of m/z 826.6 as a marker for viability in K562 
cells. 
 
Figure 4.2.8: Use of PC(36:1) + K+ to monitor viability of K562 cells. (A,B) K562 cells were 
treated with various concentrations of the indicated inhibitors and analyzed in parallel by an 
ultrafleXtreme MS and MTT assay. (A) pIC50 values derived from the concentration-response 
of m/z 826.6 were compared to MTT viability data. (B) Overlay of concentration response of 
m/z 826.6 and MTT data for imatinib treatment (mean ± SD of n = 3 biological replicates with 
8 technical replicates each).   
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4.3 DEVELOPMENT OF A LABEL-FREE CELL-BASED MECHANISTIC MALDI MS FASN ASSAY 
 
The previous section described the discovery of lipid marker molecules, which enabled the 
comparison of drug potencies. Since increases or decreases of phospholipid species can be 
induced by several stimuli, the readout becomes rather unspecific and may at best qualify as 
a phenotypic assay readout.  
The fatty acid synthase (FASN) is a relevant drug target that has been associated with several 
diseases including cardiovascular diseases [105], neurodegenerative diseases [106] and 
cancer [103]. The FASN catalyzes the following reaction: 
Acetyl-CoA + 7 Malonyl-CoA + 14 NADPH  
Palmitate + 14 NADP+ + 7 CO2 + 8 CoA 
The design of a MALDI MS enzyme assay demands some considerations that are going to be 
discussed in the following section. An MS-based cell assay requires at least one PD biomarker 
molecule from which a specific readout can be obtained. For enzyme assays these are the 
reaction educts or products. In the case of a FASN enzyme inhibition assay, method 
development towards the optimized detection of the reaction educts is justified by the expected 
dynamic range of the readout. FASN inhibition causes the accumulation of the educt malonyl-
CoA which increases its signal readily by factor 100 [76]. Monitoring the reaction product, 
palmitate is expected to result in a readout with a poor dynamic range due to the poor detection 
of endogenous fatty acids via MALDI [136]. Among the educts of the FASN reaction, acetyl-
CoA is involved in many biochemical reactions of cellular metabolism and has been proposed 
to be drawn to other pathways upon inhibition of the FASN [76]. Since the majority of metabolic 
enzymes requires NADH, NADPH is rather specific for the FASN reaction. Nevertheless, 
NADPH is also consumed by enzymes involved in purine biosynthesis, which diminishes its 
accumulation. A malonyl-CoA-based readout is proposed to be the most specific. Malonyl-CoA 
has not been described to be involved in any other metabolic pathways in human metabolism. 
Several studies previously demonstrated that cellular malonyl-CoA levels increase upon 
inhibition of the FASN [76, 137, 138]. Therefore, a malonyl-CoA-based readout is most desired 
for a FASN inhibition assay. To boost endogenous fatty acid synthesis, cells were seeded in 
lipid-free medium supplemented with 10 % charcoal-stripped FCS 16 h prior to all inhibitor 
treatment experiments as described by Hopcroft et al. [76].  
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4.3.1 OPTIMIZATION AND STANDARDIZATION OF A MALONYL-COA-BASED FASN ASSAY 
 
The sample preparation workflow was optimized to improve the detection of endogenous 
malonyl-CoA. A commercially available standard was used to test various preparation 
parameters including matrix, pH, MS ion mode and cell number. A sweet spot was reached 
when supplementing DHB matrix with 2.5 % TFA (Fig. 4.3.1). Detection of 1 fmol malonyl-CoA 
was improved when using 2.5 % TFA compared to 0.5 % TFA, whereas no malonyl-CoA was 
detected at 5 % TFA. Interestingly, the best limit of detection was obtained in positive ion mode 
even though the molecular structure of malonyl-CoA would suggest preferred detection in 
negative ion mode.  
 
Figure 4.3.1: Optimized detection of malonyl-CoA standard using 2.5 % TFA. K562 cells 
were resuspended at 5,000 cells/µl in acetonitrile/H2O (1/1) supplemented with 1 nM malonyl-
CoA. 1 µL was applied on a ground steel MTP. The plate was spray coated with DHB matrix 
(20 mg/ml in acetonitrile/H2O) supplemented with 0.5 %, 2.5 % or 5 % TFA. Sample spots were 
analyzed using an ultrafleXtreme (n = 6 technical replicates). 
 
The optimized matrix composition was used for revised establishment of the malonyl-CoA--
based FASN assay. Additionally, a potent, commercially available FASN inhibitor, 
GSK2194069, first described by Hardwicke et al. [109], was employed. Testing of 
GSK2194069 in K562 and A549 cells enabled detection of endogenous malonyl-CoA in both 
cell lines for the first time (Fig. 4.3.2). Malonyl-CoA ion intensity acquired on the ultrafleXtreme 
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MS reached a signal-to-noise ratio of 9.9 and 9.6 for A549 and K562 cells respectively (Fig. 
4.3.2 A,B). Remeasurements using the solariX FTICR MS showed a more pronounced 
response to inhibitor treatment (Fig. 4.3.2 C,D). The obtained S/N ratio of malonyl-CoA on the 
FTICR were 78.6 and 64.7 for A549 and K562 cells respectively. Importantly, no interfering 
signals were detected in high-resolution remeasurements. The superior detection of malonyl-
CoA in FTICR remeasurements is proposed to be due to the higher background observed in 
TOF data, which is in line with the higher specificity of the FTICR. 
 
Figure 4.3.2: GSK2194069 induces malonyl-CoA accumulation. A549 (A, C) and K562 
cells (B,D) were treated for 48 h with 3 µM concentrations of GSK2194069 (green spectra) and 
vehicle controls (red spectra). Cell pellets were resuspended in acetonitrile/H2O and applied 
on a ground steel MTP. The target was spray-coated with DHB matrix (20 mg/ml in 
acetonitrile/H2O/TFA (50/50/2.5)). Sample spots were measured by an ultrafleXtreme MS (A, 
B) and remeasured by a solariX FTICR MS (C,D). 
 
In FTICR MS, the putative malonyl-CoA ion was subjected to fragmentation (Fig 4.3.3), which 
enabled the assignment of several malonyl-CoA-specific fragments originating from the 
breaking of the high-energy anhydride bond and the neutral loss of adenosine diphosphate. 
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Similar fragmentation patterns have been described in the literature for the LC-MS/MS 
fragmentation of 3-hydroxyisobutyryl-CoA [139]. 
 
 
Figure 4.3.3: Fragmentation of endogenous cellular malonyl-CoA. A sample spot 
containing K562 cells treated with 3 µM GSK2194069 displayed highest ion intensity of the 
feature m/z 854.1229 and was used for FTICR MS/MS analysis.  
 
To further optimize the MALDI-TOF-based readout, measurements were consigned from the 
ultrafleXtreme to the rapifleX MALDI-TOF MS that exposed greater sensitivity and 
measurement speed. To further standardize the measurements, a commercially available 
malonyl-CoA standard with a 13C3-labeled malonyl-moiety was employed.  
Application of an internal standard using a spray device is common practice in mass 
spectrometry imaging [140]. Fingerprinting experiments enable to directly spike the standard 
to the solvent used for sample resuspension. This harbors the advantage that the standard not 
only compensates measurement related inaccuracies but also variances induced by an error- 
prone spray process. 
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Dilution of the internal standard in a cell background revealed that spiking 5 µM labeled 
standard to the solvent used for sample resuspension, yielded a signal, which was about twice 
as high as the maximum endogenous signal induced by GSK2194069 treatment. Therefore, 
samples subjected to malonyl-CoA analysis by MS were henceforth resuspended in solvent 
supplemented with 5 µM malonyl-13C3-CoA internal standard (Fig. 4.3.4 A). 
To determine the linearity of the assay readout, a dilution series of malonyl-CoA was spiked to 
a background of K562 cells, in which no endogenous malonyl-CoA was detected. Additionally, 
5 µM malonyl-13C3-CoA was spiked into each sample for normalization. MS analysis revealed 
a good linear correlation (R2 = 0.975) of the amount of spiked malonyl-CoA and the normalized 
signal at m/z 854.1 (Fig. 4.3.4 B). The concentration range in which a good linear correlation 
was observed exceeded 3 fmol/cell, suggesting that endogenous signal intensities wouldn’t 
exceed the linear detection range. 
 
Figure 4.3.4: Linear range of malonyl-CoA detection between 0.2 – 3 fmol/cell. A) K562 
cells were treated with 3 µM GSK2194069 (green spectra) and vehicle controls (red spectra) 
for 24 h. Cell pellets were resuspended in acetonitrile/H2O supplemented with 5 µM malonyl-
13C3-CoA. The suspension was applied on a MTP in 8-fold replicates and spray coated with 
DHB matrix (20 mg/ml in acetonitrile/H2O/TFA (50/50/2.5)). Samples were analyzed using a 
rapifleX MS. B) K562 cells were resuspended at 5,000 cells/µl in acetonitrile/H2O 
supplemented with various concentrations of malonyl-CoA and 5 µM of malonyl-13C3-CoA. 1 
µl of the suspension was applied on a ground steel MTP in 8-fold replicates and spray-coated 
with DHB matrix (20 mg/ml in acetonitrile/H2O/TFA (50/50/2.5)). Sample spots were measured 
by a rapifleX MS. Concentrations of the internal standard were plotted against the signal 
intensity of its protonated adduct (m/z – 854.1) normalized to the signal intensity of the 13C-
labeled standard (m/z – 857.1). Application of 1 µl of a 1 µM malonyl-CoA solution results in 1 
pmol malonyl-CoA/spot. Division by 5,000 cells/spot results in an estimated 0.2 fmol malonyl-
CoA/cell (n = 3 technical replicates, prepared and measured on different days). 
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The inhibitor incubation period was studied as the next step of assay establishment. A time 
course of GSK2194069 concentration response studies revealed that strongest malonyl-CoA 
accumulation was observed after 48 h (Fig. 4.3.5 A). Interestingly, a slight response and a 
more pronounced response are already observed after 6 and 12 h. In addition, the obtained 
pIC50 values increase with increasing inhibitor incubation periods. This implies an increased 
sensitivity with increased compound incubation time (Fig 4.3.5 B). 
 
Figure 4.3.5: Time course of GSK2194069 concentration-response. K562 cells were 
treated with various concentrations of GSK2194069 for 6, 12, 24 and 48 h. Cell pellets were 
resuspended in acetonitrile/H2O supplemented with 5 µM malonyl-13C3-CoA. The suspension 
was applied on a MTP in 8-fold replicates and spray coated with DHB matrix (20 mg/ml in 
acetonitrile/H2O/TFA (50/50/2.5)). Samples were analyzed using a rapifleX MS. A) The 
GSK2194069 concentration was plotted against the endogenous malonyl-CoA signal 
normalized to the internal standard (mean ± SD, n = 8 technical replicates). B) pIC50 values 
were calculated from non-linear fittings to the concentration response curves. 
 
To examine a homogenous distribution of the internal standard, a tool was written in R that 
displays the raw signal intensities allocated according to their arrangement on the target plate. 
Visualization of the distribution of the endogenous malonyl-CoA intensities revealed stronger 
signal intensities upon 48 h inhibitor treatment compared to 24 h inhibitor treatment (Fig. 4.3.6 
A). As expected, malonyl-CoA signal intensities decreased with decreasing inhibitor 
concentration. Interestingly, visualization of the distribution of the malonyl-13C3-CoA standard 
revealed the same trend (Fig. 4.3.6 B). Samples treated for 48 h with GSK2194069 displayed 
a strong concentration-dependent increase of the internal standard, while the intensity of the 
internal standard was more homogenously distributed in samples treated for 24 h. Longer 
inhibitor incubation induced downstream effects beyond FASN inhibition, in particular cell 
death [137].  
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Figure 4.3.6: FASN-inhibitor incubation time affects signal intensities of both 
endogenous malonyl-CoA and malonyl-13C3-CoA standard. K562 cells were seeded in 
assay medium and incubated with various concentrations of GSK2194069 for 24 h (left) or 48 
h (right). Cell pellets were resuspended at 5,000 cells/µl (cell number in control sample) in 
acetonitrile/H2O (1/1) supplemented with 5 µM malonyl-13C3-CoA. The target plate was spray-
coated with DHB matrix (20 mg/ml in acetonitrile/H2O/TFA (50/50/2.5)). Samples were 
analyzed using a rapifleX MALDI-TOF mass spectrometer. The distribution of the raw signal 
intensities of m/z 854.1 (A) and m/z 857.1 (B) were extracted and plotted in R. Signal intensities 
are illustrated as a heat map, assigned to positions on the target plate. White numbers indicate 
the micromolar GSK2194069 concentrations.  
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Cell death reduces the amount of biological material possibly resulting in less molecules that 
can suppress the ionization of the internal standard. The strong increase of the malonyl-13C3-
CoA standard therefore was taken as an indication to perform the assay with a shorter inhibitor 
incubation time of 24 h instead of 48 h. Nevertheless, the inhibitor incubation time depends on 
the expectations of the assay user. A user preferring a high S/N would probably choose a 
longer inhibitor incubation time, whereas a user preferring a more standardized readout rather 
prefers shorter incubation time. 
It is also important to take into consideration that the addition of the internal standard does not 
reduce variances induced by the loss of cellular material, even though this is a potentially huge 
source of variation. The standard was added to reduce day-to-day variances in the matrix 
application as well as variances in the mass spectrometer’s ionization and detection process. 
Intraday variances regarding, for example, the amount of cellular material would require an 
additional normalization step such as the performance of a Bradford assay. In fact, an internal 
standard can aggravate the loss of biologic material, since the resulting smaller endogenous 
signal is normalized to (i.e. divided by) an increased standard signal. 
The FASN assay contained several modifications compared to the BCR-Abl assay including 
1) cell cultivation in lipid-free medium, 2) shorter inhibitor incubations of 24 h, 3) sample 
resuspension in a solvent supplemented with 13C-labelled internal standard, 4) use of a more 
acidic matrix solvent and 5) data acquisition on a faster mass spectrometer. The final workflow 
was tested using GSK2194069 as an exemplary compound in three different weeks. The data 
enabled reproducible pIC50 determination of 7.2 ± 0.1 suggesting good repeatability of the 
workflow and suitability as an assay (Fig. 4.3.7). 
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Figure 4.3.7: Mechanistic FASN-assay enables reproducible monitoring of FASN 
inhibition. K562 cells were seeded in assay medium and incubated with various 
concentrations of GSK2194069 for 24 h. Cell pellets were resuspended in acetonitrile/H2O 
(1/1) supplemented with 5 µM malonyl-13C3-CoA. The target plate was spray-coated with DHB 
matrix (20 mg/ml in acetonitrile/H2O/TFA (50/50/2.5)). Samples were analyzed using a rapifleX 
MALDI-TOF mass spectrometer. Data extraction, plotting and pIC50 calculation was 
performed in R. A) The GSK2194069 concentration was plotted against the endogenous 
malonyl-CoA signal normalized to the internal standard. B) pIC50 values were calculated from 
non-linear fittings to the concentration response curves. The experiment was performed in 
three different weeks “week 1”, “week 2” and “week 3” (n = 3 biological replicates with 9 
technical replicates each prepared in different weeks). 
 
4.3.2 APPLICATION OF THE MECHANISTIC MALONYL-COA-BASED FASN ASSAY 
 
The workflow was applied to compare the potency of different FASN inhibitors described in the 
literature. Orlistat is an FDA-approved drug for treating obesity. Orlistat acts as a lipase 
inhibitor and prevents the uptake of fats from the human diet in the intestine [141]. Kridel et al. 
suggested orlistat as a rather selective FASN inhibitor-based on a hydrolase screen in prostate 
cancer cells, making use of a fluorescent probe that competes for binding to the thioesterase 
domain of the FASN [142]. The potent FASN inhibitor, BI 99179 (pIC50 biochemical assay = 
7.1), was discovered by Kley et al. using an in vitro HTS at Boehringer Ingelheim, which 
measures NADPH consumption in a biochemical assay [112]. Its optical antipode, BI 99990, 
exposes no FASN activity (pIC50 biochemical assay < 5.5) and was chosen as a control 
compound. It is important to note that the BI-compounds were tested in a separate tissue 
culture batch. 
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MTT analysis revealed no toxicity of the BI-compounds or GSK2194069 upon 24 h treatment 
(Fig. 4.3.8). However, viability was reduced by ~ 50 % upon treatment with 60 µM orlistat for 
24 h. 
 
 
Figure 4.3.8: Viability of inhibitor-treated K562 cells. K562 cells were treated with various 
concentrations of BI 99179 (red), GSK2194069 (blue), Orlistat (green) and BI 99990 (purple) 
for 24 h prior to viability determination by MTT assay (mean ± standard deviation for n = 3 
technical replicates). 
 
The FASN inhibition assay revealed strongest malonyl-CoA accumulation upon treatment with 
BI 99179 (pIC50 = 7.6), followed by GSK2194069 (pIC50 = 7.2) and Orlistat (pIC50 = 5.2, Fig. 
4.3.9). No inhibitory effect was observed for BI 99990, which confirmed that the optical 
antipode of BI 99179 exposes no inhibitory activity of the FASN. A comparison of the 
determined pIC50 values with values reported in the literature as well as the chosen assay 
conditions are addressed in more detail in the discussion section. 
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Figure 4.3.9: FASN assay enables potency evaluation of different FASN inhibitors. K562 
cells were seeded in assay medium and incubated with various concentrations of BI 99179, 
GSK2194069, orlistat or BI 99990 for 24 h. Inhibitor treatments with the BI-compounds were 
performed in a separate cell batch. Cell pellets were resuspended in acetonitrile/H2O (1/1) 
supplemented with 5 µM malonyl-13C3-CoA. The target plate was spray-coated with DHB 
matrix (20 mg/ml in acetonitrile/H2O/TFA (50/50/2.5)). Samples were analyzed using a rapifleX 
MALDI-TOF mass spectrometer. Data extraction was performed in R. A) Inhibitor 
concentrations were plotted against the endogenous malonyl-CoA signal normalized to the 
internal standard. B) pIC50 values were calculated from non-linear fittings to concentration 
response curves (mean ± standard deviation for n = 3 biological replicates with 9 technical 
replicates each prepared on 3 different days, n.c. - not computable). 
 
The compound BI 99179 exceeded both the potency of the GSK compound determined by 
IC50 calculation as well as the relative amount of accumulated malonyl-CoA. Since the 
experiments were performed in different cell culture batches, it was not clear whether the 
observed differences originated from the compound potency itself or variances in the response 
of different cell culture batches. The aim to develop this assay with a high focus on 
standardization justified to perform all comparisons of inhibitor potencies in the same tissue 
culture batch. The parallel evaluation of four compounds in a concentration response - 
including the required replicates - easily exceeds the workload of a single laboratory member. 
Therefore, the assay constituted a suitable example to establish an automation approach. 
 
4.3.3 AUTOMATION OF THE MECHANISTIC FASN ASSAY 
 
The conclusion that a standardized assay requires the comparison of multiple inhibitors to be 
performed in the same cell culture batch, confirmed the need for a faster and facilitated 
workflow. The aim was to develop an automated liquid handling workflow that also strengthens 
the perception of MALDI MS cell-based assays as a suitable tool for routine drug profiling.  
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HTS platforms rely on the performance assays in 384, 1536-well format and beyond [80]. As 
a proof of concept, the assay was established in 96-well format, an assay format common in 
compound profiling during lead optimization, which enables the performance of 8 
concentration-response curves, defined by 12 points each, in parallel. The assay consists of 
multiple parallelized steps (Fig. 4.3.10). In the first step K562 cells are seeded into the wells 
of a 96-well “culture-plate”. The previously established seeding density of 0.25 * 106 cells/ml 
was kept, since best drug responses were observed at this density. The seeding volume was 
reduced to 200 µl per well. The subsequent inhibitor treatment step was automated using the 
CyBio FeliX pipetting platform. Compounds were dissolved and diluted in a 96-well 
“compound-plate”. When performing a dilution series with the CyBio FeliX, tips had to be 
exchanged after each dilution step, since carry over of the compound could not be ruled out. 
1 µl of each well of the compound-plate was transferred to a respective well of the tissue culture 
plate using the CyBio 96-well 60 µL tip tray. Cell harvest was performed 24 h after inhibitor  
 
Figure 4.3.10: Automated FASN assay workflow. K562 cells were seeded in the wells of a 
96-well plate and treated with inhibitors. 24 h after inhibitor treatment culture-plates are 
centrifuged and culture supernatants are removed. Culture plates are snap-frozen. The CyBio 
FeliX pipetting platform is used to resuspend cell pellets in acetonitrile/H2O (1/1) supplemented 
with 5 µM malonyl-13C3-CoA and to apply the suspensions to a 384-well MALDI target plate. 
Sample spots were spray coated with DHB matrix (20 mg/ml in acetonitrile/H2O/TFA 
(50/50/2.5)) using a HTX spray device. Sample spots are automatically analyzed using a 
rapifleX MALDI-TOF MS. Data processing and malonyl-CoA feature extraction is performed in 
R. 
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treatment by centrifuging the culture-plates and aspirating the supernatants. Dry culture plates 
were snap-frozen. 
24 h inhibitor incubation period corresponded to approximately one doubling cycle of the K562 
cells resulting in 200,000 cells/well. To remain the established 5,000 cells per measuring spot, 
cells were resuspended in 40 µl solvent, of which 1 µl was applied to the MALDI target. As well 
as the cell number, the previously established solvent, 50 % acetonitrile in water supplemented 
with 5 µM malonyl-13C3-CoA, was kept. Several aspects were of importance for the 
implementation of the CyBio FeliX. On the one hand, sample resuspension was not sufficiently 
obtained solely by up and down pipetting of the solvent. Sample resuspension was improved 
by shaking 96-well culture-plates for 3 seconds at 2000 rpm using the instrument’s thermal 
mixer, BioShake. Moreover, the gas phase above the liquid in the pipetting tips was saturated 
by introducing a 5 s pause upon sample aspiration, which reduced the proportion of either 
dispersed or empty sample spots to less than 1 % in three independent preparations. A 
hypothetically critical aspect is the difference in viscosity of the pure solvent used for sample 
resuspension compared to the resuspended cell pellet. Greater losses of cellular material 
caused by either highly toxic compounds or inaccuracies in the sample processing might 
increase the proportion of dispersing sample spots. Additionally, the FeliX CyBio does not fully 
eject the liquid remaining in the pipette tips. This might lead to a contamination of the 
instrument’s pistons in a sequence of several pipetting steps. To omit this scenario, 10 µl air 
were aspirated prior to each pipetting step. 
Application of samples in 96-well format to a 384-well MALDI target plate enabled to apply four 
technical replicates of each sample. The sample spots were equally dispersed across the 
whole target plate (Fig. 4.3.11 A). A HTX spray device was employed to spray-coat the dried 
sample spots, since the instrument has a superior design to spray whole MALDI target plates 
compared to the SunCollect sprayer. A heated spray nozzle enabled matrix application at a 
higher flow rate, obtaining a homogenously coated target plate (Fig. 4.3.11 B). The previously 
established autoExecute function on the rapifleX MS was employed to analyze the sample 
spots. 
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Figure 4.3.11: Automation retains homogenous application of sample spots and MALDI 
matrix to a ground steel target plate. (A,B) The following liquid handling steps were 
performed using the CyBio FeliX pipetting platform: A 96-well plate containing 200,000 K562 
cells per well were resuspended in 40 µl acetonitrile/H2O (1/1) supplemented with 5 µM 
malonyl-13C3-CoA. 1 µl per measuring spot of the suspension were applied to a 384-well 
ground steel MTP in 4-fold replicates (A). The target plate was spray-coated with DHB matrix 
(20 mg/ml in acetonitrile/H2O/TFA (50/50/2.5)) using a HTX sprayer (B). 
 
The automated workflow was applied to repeat the potency evaluation of the inhibitors 
BI 99179, GSK2194069, orlistat and BI 99990. Additionally, the compound triclosan was 
included for the study. Triclosan has been described to display a superior cytotoxic profile 
compared to the FASN inhibitors Orlistat and C75 [143]. A trend that triclosan might expose a 
superior cytotoxicity compared to orlistat in K562 cells was observed in an MTT assay (Fig. 
4.3.12). 
 
Figure 4.3.12: Viability of inhibitor-treated K562 cells. K562 cells were treated with various 
concentrations of Orlistat (green) and Triclosan (grey) for 24 h prior to viability determination 
by MTT assay (mean ± standard deviation for n = 3 technical replicates). 
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The automated MALDI MS FASN assay revealed that malonyl-CoA accumulation induced by 
GSK2194069 and BI 99179 is comparable when the inhibitor treatments were performed in 
the same cell culture batch (Fig. 4.3.13 A). Potency evaluation of the inhibitors revealed that 
comparable pIC50 values were obtained by the manual and the automated workflow (Fig. 
4.3.13 B). Additionally, the error of the pIC50 value determination is comparable for both 
workflows with a standard deviation in the range of 0.1 – 0.2. Interestingly, no response was 
observed for triclosan. Previous biochemical, in vitro studies suggested that triclosan inhibits 
the ER-domain of the FASN [144]. Moreover, cell-based studies found that triclosan affects 
lipid content and lipid enzyme expression [143]. However, no study proved target engagement 
of triclosan in a cell-based context. This point is addressed with more detail in the discussion 
section of this thesis. 
A further step of assay standardization included the determination of appropriate controls to 
judge whether the response of the assay is large enough. DMSO-treated K562 cells were 
chosen as negative control. The ideal positive control would induce highest malonyl-CoA 
accumulation with minimal cytotoxic effects. The best available positive control constituted 
0.3 µM BI 99179 or 1 µM GSK2194069 treated K562 cells, a treatment with a low concentration 
of a potent compound that induces malonyl-CoA accumulation in its plateau-phase. For this 
thesis, the GSK compound was chosen, since it is commercially available. Signal intensities 
of three replicate measurements of negative and positive control were used for Z-factor 
calculation. The Z-factor was calculated according to the equation: 
𝑍 − 𝑓𝑎𝑐𝑡𝑜𝑟 = 1 −
3 • SD𝑁𝑒𝑔𝑎𝑡𝑖𝑣𝑒𝐶𝑜𝑛𝑡𝑟𝑜𝑙 +  3 •  𝑆𝐷𝑃𝑜𝑠𝑖𝑖𝑣𝑒𝐶𝑜𝑛𝑡𝑟𝑜𝑙  
|µ𝑁𝑒𝑔𝑎𝑡𝑖𝑣𝑒𝐶𝑜𝑛𝑡𝑟𝑜𝑙 −  µ𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒𝐶𝑜𝑛𝑡𝑟𝑜𝑙|
 
where SD is the standard deviation and µ are the means of the normalized readout, i.e. 
malonyl-CoA signal intensity. The obtained Z-factor was 0.61 ± 0.06 (mean ± SD for n = 3 
independent preparations (0.54/0.65/0.65)), which is considered an excellent assay related to 
screening [145]. 
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Figure 4.3.13: Automated FASN assay enables reproducible potency evaluation of 
different FASN inhibitors. K562 cells were seeded in assay medium in 96-well plates and 
incubated with various concentrations of BI 99179, GSK2194069, orlistat, triclosan and 
BI 99990 for 24 h. All inhibitor treatments were performed in the same cell batch. Cell pellets 
were resuspended in acetonitrile/H2O (1/1) supplemented with 5 µM malonyl-13C3-CoA and 
applied to a 384-well MTP using the CyBio FeliX pipetting platform. The target plate was spray-
coated with DHB matrix (20 mg/ml in acetonitrile/H2O/TFA (50/50/2.5)) using an HTX sprayer. 
Samples were analyzed using a rapifleX MALDI-TOF mass spectrometer. Data extraction was 
performed in R. A) Inhibitor concentrations were plotted against the endogenous malonyl-CoA 
signal normalized to the internal standard. B) pIC50 values were calculated from non-linear 
fittings to concentration response curves (mean ± standard deviation for n = 4 biological 
replicates with 4 technical replicates each prepared in different weeks, n.c. - not computable). 
 
The saving of time during sample preparation for the automated workflow is enormous. 
Resuspension of 96 samples and application to a 384-well plate (4-fold replicates) takes less 
than 1 minute, whereas manual resuspension of 42 samples and application to a 384-well 
plate (9-fold replicates) takes an experienced PhD student more than 1 hour. Additionally the 
automated workflow reduces the amount of required solvents and consumables. The amount 
of required assay medium per data point, i.e. treatment condition, is reduced by a factor 5. The 
use of one 96 plate for cultivation and cell harvest replaces four 24-well plates for cultivation 
and 96 Eppendorf tubes for cell harvest. 
 
4.3.4 CDP-CHOLINE AS A MARKER FOR LIPID PATHWAY INHIBITION 
 
The next step, aimed at extracting additional information from MALDI full scan mass spectra 
to further elucidate drug-action of the tested inhibitors. MALDI-TOF MS data of samples treated 
for 48 h with the confirmed FASN-inhibitors BI 99179, GSK2194069 and orlistat revealed an 
additional drug response signal at m/z 511.1, which appeared most prominently when samples 
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were spray-coated with a less acidic matrix solution. The signal clearly followed a 
concentration-dependent response (Fig. 4.3.14 A).  
A sum formula generated by MALDI-FTICR remeasurements gave evidence that the main 
underlying molecular species might be the sodium adduct of CDP-choline (C14H26N4O11P2 
+ Na+, m/z 511.0966, mass accuracy > 0.02 ppm, Fig. 4.3.14 B). This signal displayed a huge 
dynamic range in FTICR data. FTICR remeasurements also revealed two signals at m/z 
511.0755 and m/z 511.1145 in close proximity to CDP-choline, which were not resolved in 
lower resolution TOF-MS measurements.  
Due to the high abundance of the CDP-choline signal, the mass feature was isolated using the 
quadrupole of the solariX FTICR and subjected to fragmentation. These MS/MS 
remeasurements enabled assignment of several CDP-choline specific fragments, including 
fragments corresponding to the formation of the cyclophosphane ring, loss of the CDP-residue 
and breakage of the reactive pyrophosphate bond (Fig. 4.3.14 C). Due to the low abundance 
of the features at m/z 511.0755 and m/z 511.1145 structural elucidation was not feasible. The 
feature at m/z – 511.0755 may presumably be a derivate of CDP-choline, since the mass 
corresponds well to the potassium adduct of CDP-choline upon loss of a hydroxyl moiety 
(C14H27N4O10P2 + K+, mass accuracy > 0.02 ppm). The identity of m/z 511.1145 is presently 
unknown. The presence of these features is the reason why relative quantification of CDP-
choline is advised to be performed using MALDI-FTICR MS. 
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Figure 4.3.14: FASN inhibitors induce CDP-choline accumulation. A) K562 cells were 
treated with various concentrations of BI 99179, GSK2194069 and Orlistat for 48 h. Cell pellets 
were resuspended in acetonitrile/H2O (1/1) and applied to a 384-well MALDI target plate using 
a CyBio FeliX pipetting platform. The target plate was spray-coated with DHB matrix (20 mg/ml 
in acetonitrile/H2O/TFA (50/50/0.5)). Samples were analyzed using a rapifleX MALDI-TOF 
mass spectrometer. Inhibitor concentrations were plotted against the signal at m/z 511.1 
(mean ± standard deviation for n = 4 biological replicates with 4 technical replicates each 
prepared in different weeks). B) FTICR mass spectra of 1 µM BI 99179 (green) and control-
treated (red) K562 cells reveal the presence of mass features that interfere with low resolution 
TOF-MS measurements. C) A sample spot containing 1 µM BI 99179 treated K562 cells 
exposed highest feature intensity of m/z 511.1 and was used for FTICR MS/MS 
remeasurements. 
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The link between CDP-choline accumulation and FASN inhibition was found in the literature. 
The enzyme CDP-choline phosphotransferase (CPT) catalyzes the final step of 
phosphatidylcholine synthesis using diacylglycerol (DAG) and CDP-choline as its substrates 
(Fig. 4.3.15, [146]). Inhibition of fatty acid synthesis at any step in the pathway causes 
decreased levels of DAG, resulting in an accumulation of not converted CDP-choline. 
Therefore, CDP-choline constitutes an interesting phenotypic marker for lipid pathway 
inhibition in K562 cells rather than a mechanistic target-specific marker. 
 
 
Figure 4.3.15: Membrane lipid synthesis and the Kennedy pathway. Lipid synthesis and 
the Kennedy pathway are brought together by the CDP-choline phosphotransferase (CPT). 
The enzyme catalyzes the reaction of diacylglycerol (DAG) and CDP-choline to 
phosphatidylcholine (PC). DAG is formed from acetyl-CoA by the successive action of acetyl-
CoA carboxylase (ACC), fatty acid synthase (FASN), acyl-CoA synthetase (ACS), glycerol-3-
phosphate acyltransferase (GPAT), acylglycerophosphate acyltransferase (AGPAT) and 
phosphatidic acid phosphohydrolase (PAP). CDP-choline is formed from choline by 
successive action of choline kinase (CK) and CTP:phosphocholine cytidylyltransferase (CCT). 
 
CDP-choline accumulation is an interesting marker to provide additional evidence that the 
FASN-reaction was indeed inhibited. A conceivable counterargument might be that malonyl-
CoA accumulation was observed due to an induced overproduction of malonyl-CoA. However, 
CDP-choline accumulation gives further evidence that the target was indeed the lipid 
synthesis. Therefore, all compounds that were previously examined for malonyl-CoA 
accumulation were re-evaluated. Moreover, the fact that DAG is not the direct product of the 
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FASN reaction gave rise to the hypothesis that CDP-choline accumulation might also be 
caused by other inhibitors of the lipid synthesis pathway. Therefore, the rather specific acetyl-
CoA carboxylase (ACC) inhibitor 5-(tetradecyloxy)-2-furoic acid (TOFA) [147] was tested in 
addition to the previously tested inhibitors. 
CDP-choline accumulation was observed not only for the FASN inhibitors BI 99179, 
GSK2194069 and orlistat but also for the acetyl-CoA carboxylase inhibitor TOFA, another 
inhibitor of the lipid synthesis pathway (Fig 4.3.16). A trend of CDP-choline accumulation was 
also observed for triclosan, but it consistently occurred at concentrations where the cellular 
viability was below 50 %. 
 
Figure 4.3.16: Inhibition of lipid synthesis causes CDP-choline accumulation. K562 cells 
were treated with 30 µM of TOFA, triclosan and orlistat as well as 1 µM of BI 99990, BI 99179 
and GSK2194069 and analyzed using a solariX MALDI-FTICR mass spectrometer. Treatment 
conditions were plotted against the intensity of the signal at m/z 511.097 (mean ± standard 
deviation for n = 3 biological replicates prepared in different weeks, asterisk indicates that 
cellular viability was below 50 %). 
 
With the combined detection of malonyl-CoA and CDP-choline the developed assay 
constitutes a relevant example for the diversity of the metabolite-based MALDI MS cell assay 
readouts. On the one hand, the malonyl-CoA signal provides mechanistic information on the 
drug action while CDP-choline is a rather phenotypic marker for drug action.  
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4.3.5 ADAPTATION OF THE DEVELOPED MECHANISTIC FASN ASSAY FOR A549 CELLS 
 
Over the past years, the discovery of potent FASN-inhibitors has been a relevant research 
topic in the pharmaceutical industry [148]. Since CML and, hence, K562 cells are not relevant 
for FASN inhibitor discovery, which rather targets solid tumors, the automated FASN assay 
was implemented for the adherent lung cancer A549 cell line as well. 
Since the A549 cell line is an adherently growing cell line, minor modifications were 
implemented in the automated workflow: Cell detachment was achieved by snap-freezing the 
96-well “culture plates” and vigorous vortexing during sample resuspension. These two steps 
were already implemented for the K562 cell-based assay. However, A549 cells could not be 
seeded at similar cell numbers as the K562 cells. If A549 cells were seeded at 0.25 x 106 
cells/ml, they were already confluent on the day of inhibitor treatment and overly confluent 
upon cell harvest. The seeding volume of 200 µl/well was not reduced on purpose to keep the 
concentration of the vehicle, DMSO, as low as possible. Therefore, the seeding density was 
reduced to 0.1 x 106 cells/ml. This measure resulted in a lower amount of cellular material per 
measuring spot and a hardly acceptable Z-factor of 0.06. This effect was counteracted by the 
application of 2 µl sample per measuring spot which drastically improved the Z-factor to 0.58. 
The developed FASN assays for K562 and A549 cells were used for a compound profiling in 
parallel. The less specific FASN-inhibitor C75 [149] and G 28UCM [150] were included to 
assess whether the mechanistic FASN cell assay uncovered these kinds of inhibitors as well. 
Moreover, we decided to include the previously tested inhibitor GSK2194069 as quality 
measure whether the assay performed well and the previously determined pIC50 value was 
reproduced. We also decided to test the previously published inhibitor GSK837149A which 
was published as a potent inhibitor of the purified human FASN with impaired cellular 
permeability [73].  
All inhibitors were evaluated in three biological replicates (Fig. 4.3.17). The pIC50 value of 7.1 
for GSK2194069 previously determined in K562 cells was accurately reproduced (Fig. 4.3.17 
A). The Z-factors of the assay performed in K562 cells (Z-factor = 0.56, 0.82, 0.41) were lower 
than for the previous set of experiments but still in an acceptable range. Z-factors determined 
in A549 cells (Z-factor = 0.85, 0.65, 082) were excellent, suggesting a reliable evaluation of 
the compounds (Fig. 4.3.17 B). 
For GSK837149A no FASN inhibition was observed, supporting the hypothesis that this 
compound was not membrane permeable and displayed no cellular activity despite its high 
potency in a biochemical enzyme assay (pIC50 = 7.8 [73]). For C75 and G 28UCM no pIC50 
values were determinable in either of the tested cell lines. The presumably low cellular potency 
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and selectivity of these inhibitors may require an evaluation using different inhibitor 
concentrations and incubation times. Interestingly, the pIC50 values for GSK2194069 
determined in K562 cells (pIC50 = 7.1 ± 0.1) were slightly higher in A549 cells (pIC50 = 7.5 ± 
0.1), indicating a stronger response of the A549 cells. The underlying reason can only be 
hypothesized and will be addressed in more detail in the discussion section. Finally, the aim 
was to confirm that the increased malonyl-CoA levels indeed originate from an increased 
inhibition of the FASN and consequently an inhibition of lipid synthesis. Therefore, 
accumulation of the previously established marker for lipid pathway inhibition, CDP-choline, 
was measured using a MALDI-FTICR MS (Fig. 4.3.17 C, D). CDP-choline accumulation was 
confirmed in both cell lines for GSK2194069. 
 
Figure 4.3.17: Transferability of mechanistic cell assay from K562 cells to adherently 
growing A549 cells. K562 (A) and A549 cells (B) cells were seeded in assay medium in 96-
well plates and incubated with various concentrations of G 28UCM, C75, GSK2194069 and 
GSK837149A for 24 h. Cell pellets were supplemented with 5 µM malonyl-13C3-CoA and 
applied to a 384-well MTP using the CyBio FeliX pipetting platform. The target plate was spray-
coated with DHB matrix (20 mg/ml in acetonitrile/H2O/TFA (50/50/2.5)) using an HTX sprayer. 
Samples were analyzed using a rapifleX MALDI-TOF mass spectrometer. Data extraction was 
performed in R. Inhibitor concentrations were plotted against the endogenous malonyl-CoA 
signal normalized to the internal standard (mean ± standard deviation for n = 3 biological 
replicates with 4 technical replicates each prepared on different days). C,D) Sample spots 
containing 1 µM inhibitor treated K562 cells (C) and A549 cells (D) were spray-coated with 
DHB matrix (20 mg/ml in acetonitrile/H2O/TFA (50/50/0.5)) and remeasured using a solariX 
MALDI-FTICR mass spectrometer. Treatment conditions were plotted against the intensity of 
the CDP-choline signal (mean ± standard deviation for n = 3 technical replicates). 
- 91 - 
5 DISCUSSION 
 
5.1 A METABOLITE-BASED IC-MALDI MS FINGERPRINTING WORKFLOW 
 
AlMasoud et al. described that the establishment of a new MALDI MS method including the 
evaluation of matrices, solvent additives and application methods, requires the performance 
of several thousands of experiments, which they could reduce to several hundred key 
experiments by fractional factorial design [46]. The remaining several hundreds of experiments 
still constitute a considerable expenditure of resources, which in this thesis was omitted by 
adapting and prospering from MALDI sample preparation methods described in the literature. 
Three cancer cell lines were prepared according to multiple preparation protocols. Score-
based method evaluation was performed to develop a reproducible and sensitive IC-MALDI 
MS fingerprinting workflow. 
The discipline of metabolite-based MALDI MS cell assays is still in its infancy. Prior to the 
publication of this work, three publications outlined in the introduction described preparation 
protocols for whole cell lipid measurements by MALDI MS [31, 33, 34]. Both Angelini et al. as 
well as Lobasso et al. used 9-amino acridine (9-AA) as a vacuum stable matrix, suitable for 
IC-MALDI MS measurements, enabling the detection of multiple negatively charged lipid 
classes. Since 9-AA is a DNA-intercalating ligand, which is known to cause mutations [151], 
the use of 9-AA is often not a viable option. Especially the aim for larger scale sample 
preparations and matrix application using spray devices affirmed the search for alternative 
matrix preparation protocols. Sakai et al, relied on the use of 2,6 dihydroxyacetophenone 
(DHAP). DHAP is a non-vacuum stable matrix [152]. DHAP might be suited for the analysis of 
relatively small sample sizes, as in the study done by Sakai et al. for the analysis of single 
concentration and single drug treatment or for MALDI instruments with atmospheric pressure 
ion sources. The aim to develop a workflow applicable for the analysis in 384-well format 
required a more vacuum stable matrix. 6-aza-2- thiothymine (ATT) has been described as a 
superior matrix for the detection of glycosphingolipid species in lipid extracts [38]. The ATT 
matrix also revealed good results for the discrimination of three cancer cell lines as evaluated 
by Joverlap score. However, DHB matrix was chosen as the preferred matrix as elaborated by 
Joverlap and MSEmod scores. 
MALDI MS imaging (MSI) is a rapidly growing technology [153], which is mostly applied for the 
analysis of tissue sections in a clinical or pharmacological context. The discipline’s increased 
awareness for a need of standardization [47] and improved sensitivity [154] provided valuable 
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ideas that were repeatedly tested for implementability into a MALDI MS fingerprinting workflow 
during the course of this thesis. The use of a matrix sprayer, which is used to coat tissue 
sections with matrix for MSI experiments, worked well for the coating of ground steel MALDI 
target plates and led to the formation of homogenously distributed matrix and analyte signals. 
The adaptation of the scores Joverlap [47] and MSE [49] which also were first described in 
publications related to MS imaging were swiftly implemented and highly valuable for a 
standardized method development. An approach to monitor reproducible matrix application by 
digital microscopy was presented. Future developments, ideally of the development of a 
pattern recognizing software, are going to be required to standardize this quality measure. 
The biologic starting material for method development were harvested cell pellets of three 
cancer cell lines, including the gastrointestinal stroma tumor cell line GIST T1 and the two 
leukemia cell lines K562 and HL60. With the aim to develop a method that reproducibly detects 
as many metabolites as possible from these specimens, Joverlap and MSEmod optimization was 
performed. Gastrointestinal tumor cells and leukemia cells are expected to expose striking 
metabolic differences. However, these differences were diminished and altered by cultivation 
in cell culture media mainly supplemented with FCS. Previous work showed that cultivating 
the gastrointestinal cell line SGC7901 in both RPMI1640 and DMEM already caused distinct 
changes of the metabolome [155]. Moreover, an additional study reported that cultivation of 
cells in a developed human plasma like medium caused widespread changes in the 
metabolome compared to cultivation in traditional medium [124]. The authors reference to 
multiple studies that describe the influence of environmental metabolites on the cellular 
metabolome. In summary, these results suggest that a more pronounced separation in PCA 
space is expected if, for example, primary gastrointestinal and primary blood cells are 
subjected to the developed fingerprinting workflow. 
Furthermore, the developed method had a strong focus on an exploratory metabolome 
analysis and therefore was of interest for the discovery of unknown response markers. A 
contrasting example constitutes the development of an assay to monitor the inhibition of the 
fatty acid synthase, which required malonyl-CoA as its readout. In this scenario, a method that 
detects as many metabolites as possible, but only poorly detects malonyl-CoA would not be 
conducive. Therefore, it is important to note that while the chosen method development 
approach was relevant for exploratory metabolome analysis. Analysis with a different scientific 
expectation might require a different method development approach, e.g. the employment of 
a commercially available standard for targeted measurements. Moreover, the condition of the 
MALDI instrument, including system purity and laser fluence have been described to cause 
differences in the acquired mass spectra [156], which aggravates the reproducible acquisition 
of mass spectra. Especially the chosen laser fluence affects the full scan mass spectrum, 
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shifting signals of intact analytes to signals of fragmented analytes at high laser fluence [136], 
which again highlights the need for internal standards in targeted MALDI MS measurements. 
Direct infusion ESI MS experiments have been described to detect 4720 m/z features which 
were annotated to 962 metabolites by matching the accurate mass [157]. The focus of this 
thesis was not a comprehensive identification of all observed m/z features. A typical MALDI-
FTICR spectrum of K562 cells contained 10,000 m/z features (4 M AMP transient, m/z 150 – 
5,000) of which 15 metabolites were annotated by matching the accurate mass. Moreover, 4 
metabolites were confirmed by FTICR MS/MS remeasurements. Further studies are required 
to assess to which extend the entirety of features observed in a full-scan FTICR spectrum 
covers the human metabolome. Since all MS analyses for this thesis were conducted in 
positive ion mode, metabolite coverage might be increased by implementing novel matrices 
described for negative ion mode [158, 159] or the use of dual polarity matrices that have been 
described for both positive and negative ion mode [160]. Additionally, optimized sensitivity 
harbors the potential to broaden the coverage of detected metabolites. Even though MALDI 
MS has been described as a rather impurity tolerant method [8], highest sample purity would 
be required for maximum sensitivity [161]. 
A central challenge during the development of a metabolite-based MALDI-fingerprinting 
workflow was the presence of interfering matrix ions as elaborated by MSEmod scores. Besides 
alternative surface ionization technologies like desorption electrospray ionization mass 
spectrometry (DESI) and secondary ion mass spectrometry (SIMS), which follow a different 
ionization mechanism, alternative energy absorbing materials to reduce the matrix background 
are being developed. Carbon nanotubes have been found to transfer energy upon laser 
irradiation and to eliminate interfering matrix ions [162]. Oxidation of these carbon nanotubes 
has been described to further advance desorption / ionization of an amino acid mixture. 
Moreover, the oxidized carbon nanotubes exposed greater solubility in aqueous solutions 
[163]. Also other nanomaterials like silica beads and fullerenes [164] as well as surfaces 
coated with inorganic particles like gold, iron, titanium oxide or zinc oxide have been described 
as substitutes for established MALDI matrices [165]. In light of this great variety, it remains to 
be elucidated which of these emerging technologies will prevail. Conceivable is also a 
combination of surface coating and MALDI matrices, to further enhance sensitivity. A former 
high throughput biochemical HDAC assay made use of gold-coated surfaces in combination 
with MALDI mass spectrometry. The enzyme substrate was immobilized to the gold particles 
via a thiolate bond enabling on target washing and efficient desorption upon laser irradiation 
[166]. 
Spray-coating of DHB matrix was chosen since matrix applied as a liquid droplet formed 
crystals at its outer ring; a phenomenon commonly known as the coffee stain effect. The coffee 
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stain can also be prevented by electrowetting where an electric field generates an internal flow 
that counteracts the evaporation-driven flow and depins analytes from the outer contact line of 
the droplet. Kudina et al. published that an electrowetting MALDI approach enabled 2-30 fold 
enhanced MALDI MS signals [41]. Currently no electrowetting MALDI capable and Bruker 
instrument compatible MALDI target plates are available and might thus be an interesting 
approach for future experiments. Moreover, addition of benzoic acid has been observed to 
lead to a homogenous matrix crystallization without the need for a matrix sprayer. However, 
similar to the published DHAP matrix, the benzoic acid approach was not further pursued since 
benzoic acid is not vacuum stable and therefore not applicable for time consuming analysis in 
384-well format. Technological advances in data recording and data processing enable a faster 
sample readout. As described in the introduction section technological advances go hand in 
hand with advances in the development of novel assays and might therefore empower 
reevaluation of previously declined approaches.  
 
5.2 THE PHENOTYPIC BCR-ABL TYROSINE KINASE INHIBITION ASSAY – AN EXAMPLE OF 
PHENOTYPIC DRUG DISCOVERY BY MALDI MS? 
 
The developed fingerprinting workflow was applied to monitor drug action of tyrosine kinase 
inhibitors in K562 cells in 384-well format. An automated data processing pipeline was 
developed to extract concentration response marker molecules. The putative marker 
molecules were structurally elucidated by high resolution MALDI-FTICR MS/MS. 
The two features, heme B and PC(36:1) + K+ were identified as ascending and descending 
concentration response marker molecules respectively. The induction of heme B was 
hypothesized to originate from erythropoiesis of K562 cells. Heme B is the prosthetic group of 
hemoglobin [167]. Hemoglobin synthesis has previously been linked to erythropoiesis in K562 
cells [168]. In previous publications erythropoiesis was monitored by heme or hemoglobin 
detection using a specific reaction with benzidine / hydrogen peroxide solution [169]. 
Intracellular heme concentrations are tightly regulated due to the toxicity of free heme [170]. 
Hietakangas et al. reported that K562 cells lost resistance to TNFα induced apoptosis upon 
erythroid differentiation [171]. In contrast, Bonovolias et al. concluded that erythroid 
differentiation protects K562 cells from imatinib induced cell killing [172]. The antithetical study 
outcomes indicate that the differentiation state determines the sensitivity to different 
antiproliferative agents. 
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The reason why the most pronounced decrease was observed for PC(36:1) + K+ of all features 
is likely linked to cell death. Cristea et al. previously described that cell death is accompanied 
by the expression of lipid degrading enzymes [131]. However, the spectra of imatinib treated 
K562 cells contain multiple lipid signals, most of which show no or no response comparable to 
PC(36:1) + K+. The protonated adduct and the sodiated adduct of PC(36:1) were also observed 
but do not show a decrease of signal intensity comparable to the potassiated adduct. Another 
lipid that also showed a prominent decrease was the potassium adduct of PC(34:1). Wang et 
al. described that apoptotic events impair Na+/K+ ATPase activity [132]. This might cause a 
loss of intracellular potassium, leading to a significantly reduced amount of K+ adduct 
formations during the MALDI process. It still remains to be elucidated if all isomeric species of 
PC(36:1) + K+ are equally affected by the decrease. The answer of this question would require 
the implementation of novel analytical techniques like ion mobility. Future work might for 
example involve Bruker’s trapped ion mobility MS (TIMS) TOF, which may enable separation 
of the isomeric lipid species 18:1 (Δ-9) PC and 18:1 (Δ-6) PC11.  
Breitkopf et al. performed a triomics study, which included metabolomic, lipidomic and 
phopsphoproteomic analysis on imatinib treated myeloma cells [102]. The authors observed a 
reduction of lipid biosynthesis and incorporation of fatty acids into lysophospholipids as well 
as upregulation of some phosphatidylethanolamine species. Metabolomic analysis revealed 
that few metabolite levels were significantly affected. The most striking increase was observed 
for precursors of the nucleotide synthesis whereas acetyl-CoA and NADPH levels were 
decreased. Moreover, in a more recent study Noel et al. compared the metabolome of wild 
type and imatinib resistant K562 cells [173]. The authors correlated increased levels of 
glycolytic intermediates including glucose 6-phosphate, fructose 6-phosphate and fructose 
1,6-bisphosphate to an increased imatinib resistance. These results highlight negatively 
charged ions like phospatidylethanolamines, metabolites of the glycolysis and nucleotide 
precursors as putative marker molecules. In summary, MALDI MS cell-based assays harbor a 
broad range of target molecules as phenotypic concentration response markers. 
The observed lipid marker molecules are a very indirect readout for BCR-Abl inhibition. A direct 
link between lipid synthesis and BCR-Abl signaling was provided by Burns et al. [174]. The 
authors observed an increased expression of the sphingomyelin synthase (SMS) in K562 cells. 
Since SMS knock down by siRNA inhibited the proliferation of BCR-Abl positive cells, they 
concluded that SMS is a downstream target of BCR-Abl. A similar study would not be feasible 
for PC synthesis since PCs are an essential component of the plasma membrane [175]. From 
a signaling pathway perspective, the primary pathways affected by BCR-Abl inhibition are the 
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(Pi3K)/AKT, the RAS and the MEK pathway as reviewed by Cilloni et al. [176]. The inhibition 
of survival promoting factors, like AKT, leads to a reduced phosphorylation of key apoptosis-
regulatory proteins and thus activates the signaling cascade towards cell death [177]. At the 
end of a cascade involving death receptor activation, formation of a death inducing signaling 
complex and recruitment of caspases occurs the observed degradation of membrane lipids, 
accompanied by DNA fragmentation and other biochemical changes [176]. The multitude of 
involved enzyme cascades highlights that the observed treatment effect is highly indirect. 
Therefore, the observed markers can be considered as phenotypic markers.  
Phenotypic drug discovery has strongly contributed to drug discovery in previous years [60]. 
The prerequisite for a phenotypic assay is the identification of an appropriate phenotypic 
readout. This thesis presents an exemplary workflow how MALDI MS can discover novel 
phenotypic markers in a cell-based assay. Therefore, the workflow rises expectations to enable 
the extraction of phenotypic, biomolecular markers from other cellular models relevant for drug 
discovery, including genetically engineered cells [178], induced pluripotent cells [179] and 
organoid cultures [180], in a throughput oriented approach. Especially challenging is the 
development of test systems for neurologic diseases and heterogeneous tumors [59]. Even 
though MALDI MS has been established as a versatile readout for complex biological samples 
[181], it remains to be elucidated if MALDI MS will provide pharmacologically predictive models 
for these diseases. 
The feasibility of metabolite-based IC-MALDI MS drug assays has not been described before 
[121]. Our study demonstrates that the technology has the potential to support cell-based 
profiling for drug discovery. Additionally, the developed workflow enabled reproducible potency 
evaluation of selected BCR-Abl inhibitors. The awareness for the need of a higher specificity 
was elaborated in this thesis and addressed with the development of a FASN assay. 
 
5.3 THE MECHANISTIC FASN INHIBITION ASSAY – A PERSPECTIVE IN DRUG DISCOVERY? 
 
During this thesis an assay to monitor the inhibition of the fatty acid synthase (FASN) directly 
in whole cells was developed. Further method development enabled the standardized and 
reproducible detection of malonyl-CoA as the readout of the assay. Exploratory analysis of full-
scan spectral data enabled the identification of CDP-choline as a marker for lipid pathway 
inhibition.  
The observation of CDP-choline was an unexpected finding during FASN-assay 
establishment, supporting the potential of the developed, exploratory MALDI-TOF MS 
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workflow. Increased CDP-choline levels were previously observed in erythrocytes. In 1983, 
Paglia et al. first described the accumulation of CDP-choline in the erythrocytes from a woman 
with hemolytic anemia [182]. The authors hypothesized an inherited choline 
phosphotransferase (CPT) deficiency. Petersen et al. observed CDP-choline accumulation in 
another case of haemolysis and could provide evidence for a CPT defect using 31P-NMR 
spectroscopy and enzymatic analysis [183]. Boggs et al. observed an inhibition of the CDP-
choline pathway along with reduced choline incorporation into phospholipids upon treatment 
with lysophosphatidylcholine [184]. However, CDP-choline was not yet described as a marker 
for lipid pathway inhibition. Moreover, CDP-choline has been described to accumulate in 
erythrocytes. Our study on A549 cells suggests that CDP-choline also functions as a marker 
for lipid pathway inhibition in epithelial cells. The marker might be valuable for exploratory 
studies on the lipid-synthesis pathway for example as a readout for rescue assays of inhibited 
lipid enzymes. 
Sadowski et al. proposed triclosan as a FASN inhibitor to target prostate cancer [143]. The 
authors described a superior cytotoxic profile compared to orlistat, increased expression of 
genes involved in fatty acid metabolism and observed an overall decrease of lipid levels upon 
triclosan treatment. Still sufficient proof that triclosan indeed targets the intracellular FASN was 
not provided. Triclosan also exposed a higher cytotoxicity compared to orlistat in our hands 
but no detectable malonyl-CoA accumulation. The observed CDP-choline accumulation 
suggests that triclosan targets one or several enzymes in the lipid synthesis pathway. Since 
no malonyl-CoA accumulation was observed FASN inhibition was not confirmed. Interestingly, 
Sadowski et al. observed a rescue of triclosan induced growth inhibition by addition of 
palmitate. This rises the hypothesis that triclosan might target a step prior to fatty acid 
synthesis, namely the acetyl-CoA carboxylase mediated formation of malonyl-CoA. On the 
other hand, the comparably simple molecular structure of triclosan might be an evidence for a 
rather unspecific inhibitor of the lipid pathway. 
The pIC50 value determined by the response of malonyl-CoA accumulation upon FASN 
inhibition has been observed to increase with inhibitor incubation time. Acyl-CoA esters have 
been described as an allosteric inhibitor of the malonyl-CoA producing enzyme acetyl-CoA 
carboxylase (ACC) [185]. A lower cellular lipid content, might decrease ACC inhibition and thus 
further activate malonyl-CoA accumulation via a positive feedback mechanism. 
Potency evaluation of various FASN inhibitors was performed both manually in 24-well format 
and, with support of an automated pipetting platform, in 96-well format. Comparison of the 
results of both potency evaluations revealed almost identical pIC50 values. When experiments 
were performed manually, a separate culture batch originating from a different cryo-stock was 
used for treatment with Boehringer Ingelheim compounds. Even though the determined pIC50 
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value was not affected by the use of a separate cryo-stock, results indicated a more 
pronounced area under the curve (AUC), i.e. malonyl-CoA accumulation, upon treatment with 
BI 99179 compared to GSK2194069. Repeated evaluation performed in parallel revealed a 
comparable malonyl-CoA accumulation for both compounds. Previous studies tested various 
machine learning algorithms on publically available screening datasets to build a model that 
predicts drug-sensitivity of cancer cell lines12. The factor that affected the predictive outcome 
the most were the molecular features provided by different laboratories followed by the choice 
of the algorithm. In line with these findings is a critical review of the reproducibility in high 
throughput cancer drug screening [186]. The authors concluded a poor intralaboratory 
concordance in the drug response phenotypes and referenced to two HTS studies, namely the 
Cancer Cell Line Encyclopedia and the Cancer Genome project. Comparison of both projects 
revealed similar gene-expression profiles for the tested cell lines but inconsistent drug 
responses. Besides differences in the sample preparation protocol and compound storage, the 
authors name variations in cell cycle, passage number and growth rate as factors that can 
affect drug responsiveness. In summary, standardization is a key factor for reproducible assay 
performance. This requires on the one hand to always follow the same, comprehensively 
logged preparation protocol. Moreover, standardization requires testing of compounds under 
as comparable conditions as possible. This includes compound dispensing, storage [187] and 
application but also treatment time point and incubation time. Despite these standardization 
approaches, monitoring a quality assurance factor like Z-factor is vital to warrant that the 
assays response was sufficient. The pIC50 value of GSK2194069 (pIC50 = 7.1 ± 0.1) was 
reproduced in 6 manual and 6 automated preparations of K562 cells. The mean Z-factor for 6 
automated preparations (0.61 ± 0.13) with only one Z-factor below 0.5, suggests excellent 
overall performance of the assay. 
Interestingly, the pIC50 value generated for the potency of GSK2194069 in A549 cells (pIC50 
= 7.5) agrees well with the value published by GSK (pIC50 = 7.8 [109]). To determine the 
pIC50 value, researchers at GSK measured phosphatidylcholine levels of A549 cells upon 48 
h incubation of the compound. The GSK Company had chosen inhibitor treatment conditions 
which were comparable to the conditions elaborated in this thesis. Therefore the accordance 
of the generated pIC50 values was an important validation of the developed assay. Boehringer 
Ingelheim’s platform (www.opnMe.com) provides a pIC50 of 6.7 for the cellular FASN inhibition 
by BI 99179. The specified pIC50 deviates by almost one order of magnitude from the pIC50 
obtained in our assay (pIC50 = 7.6). This is likely due to the fundamentally different approaches 
to determine cellular FASN inhibition. Scientists at Boehringer Ingelheim measured the 
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incorporation rate of 14C-acetate into cellular lipids upon inhibitor treatment, which is a more 
sensitive but also an indirect readout. Moreover, inhibitor incubation was performed for only 1 
h using mouse hypothalamic N-42 cells [112]. Previous experiments revealed an increase of 
pIC50 values with increasing inhibitor incubation time (Fig. 4.3.5). 
For automation purposes, cells were treated in 96-well plates. Cell harvest was performed by 
centrifuging the culture-plates and aspirating the supernatants. Centrifugation is notoriously 
difficult to implement into automated assay workflows. For the purpose of establishing such a 
workflow, removing culture supernatants by filtration might also be considered [188]. 
Noteworthy the A549-based assay exposed a stronger response to the tested inhibitor, 
GSK2194069, compared to the K562-based assay. The underlying reason can only be 
hypothesized. Responses of established cancer cell lines to anti-cancer drugs have been 
systematically studied as part of the NIH funded LINCS program (Library of Integrated 
Network-Based Cellular Signatures) [189]. Multiple genotypic markers have been identified 
whose presence was connected with drug responsiveness. Especially responses to drugs 
targeting intracellular signaling kinases have been found to be cell type specific [190]. Studies 
indicate that both the cellular localization and activity of the FASN is regulated by 
phosphorylation as well as protein-protein interactions [148]. Prominent kinases that have 
been described to phosphorylate FASN include the human epidermal growth factor receptor 2 
(Her2) [191] and a nutrition-dependent phosphorylation by the mammalian target of rapamycin 
(mTOR) [192]. Additionally, a study conducted with sera from patients with different tumor 
types and healthy controls revealed that Non-Small Cell Lung Cancer tumors are associated 
with especially high FASN expression levels [148]. Moreover, during the course of this thesis 
was observed that pIC50 values depend on the inhibitor incubation time. A similar dependency 
might exist for the seeding density of the respective cell line and therefore systematically shift 
the observed pIC50. In summary, this study highlights that a precise drug-potency 
determination not only depends on the cell type but also on the cellular state and chosen assay 
conditions, which again highlights that a high degree of standardization is vital for the 
reproducibility of MALDI MS cell-based assays. 
5 years ago Munteanu and Hopf raised the question if MALDI MS cell assays are going to be 
an emerging technology for HTS [3]. Although this question still cannot be answered with 
certainty, there are many indications of major advances in near future which will further 
promote the attractiveness of the technology. Cell cultivation for the assay reported in this 
thesis was performed in 96-well format. Further miniaturization of the assay is absolutely 
conceivable, as first publications already reported the use of MALDI MS on the single cell level 
[193, 194]. Additionally, a strength of the developed cell-based assay compared to biochemical 
assays was the intrinsic validation that the compound is cell permeable. Another advance will 
- 100 - 
be the throughput-oriented screening of active ingredients in organoid cultures. Several studies 
already opened up possibilities for the use of organoids on a chip for drug discovery, such as 
3D cultures to model the intestinal physiology [195] or blood-brain-barrier organoids to 
investigate the permeability of therapeutics targeting the central nervous system [196]. Due to 
its versatile readout, MALDI MS has also been implemented into multiplexing and array 
technologies. MALDI MS arrays have previously been implemented to monitor biochemical, in 
vitro assays [197] as well as for the classification of tumor sections [198]. Considerations to 
develop chip-based MALDI MS cell arrays would go hand in hand with the previous approach 
of assay-miniaturization. 
Overall the results of the developed mechanistic FASN assay are encouraging and suggest 
that the automated workflow could be established as a routine workflow for cell drug assays. 
The automated workflow also is of interest from an industrial HTS perspective. Long-term 
evaluations are going to be required to assess instrument reliability and robustness.   
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